Access DB# 142614

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabiha Qazi Examiner #: 74141 Date: 12/1/05

Art Unit: 1616 Phone Number 30 28622 Serial Number: 09/917,403

Mail Box and Bldg/Room Location: 4C70, Rem, 4A45 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: Epoxy-steroidal - - - - - -

Inventors (please provide full names): J. C. Alexander et al.

Earliest Priority Filing Date: 7/27/00

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.* Elected → eplerenone + metoprolol combination

Please search for the combination of eplerenone and Beta adrenergic antagonist as in cl 1. pharmaceutical composition and method of treating cardiovascular disorder by said combination

1. Cls 48 - 51, 63+64 → method of treating
2. Composition → Cls 53 - 61 + 42
3. Combination → Cls 1, 9 - 20

Please see attached sheet

Thank You

Please see 10/343,166

****

STAFF USE ONLY		Type of Search		Vendors and cost where applicable	
Searcher:	Jan	NA Sequence (#)		STN	✓
Searcher Phone:	22504	AA Sequence (#)		Dialog	
Searcher Location		Structure (#)	✓	Questel/Orbit	
Date Searcher Picked Up	1/19/05	Bibliographic	✓	Dr Link	
Date Completed	1/19/05	Litigation		Lexis/Nexis	
Searcher Prep & Review Time		Fulltext		Sequence Systems	
Clerical Prep Time	20	Patent Family		WWW/Internet	
Online Time	+65	Other		Other (specify)	

PTO-1590 (3-01)

```
=> d his

     (FILE 'HOME' ENTERED AT 07:29:42 ON 19 JAN 2005)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 07:29:51 ON 19 JAN 2005
L1             1 S EPLERENONE/CN
L2            62 S 107724-20-9/CRN
L3            26 S L2 AND MXS/CI
L4            26 S L2 AND MIX?
L5            26 S L3,L4
L6            36 S L2 NOT L5
L7             1 S 51384-51-1
L8            33 S 51384-51-1/CRN
L9            14 S L8 AND (MXS/CI OR MIX?)
L10           19 S L8 NOT L9
                 E C15H25NO3/MF
L11           10 S E3 AND 46.150.18/RID AND 1/NR AND 2 PROPANOL AND 4 2 METHOXYE
L12            4 S L11 AND METHYLETHYL
L13            3 S L12 NOT 11C
                 SEL RN
L14           47 S E1-E3/CRN
L15           14 S L14 NOT L8
L16            1 S L15 AND (MXS/CI OR MIX?)
L17           13 S L15 NOT L16
L18           11 S L17 NOT C20H18O8
L19           30 S L18,L10
L20           17 S L8,L14 NOT L19
L21           21 S 29122-68-7 OR 66722-44-9 OR 36894-69-6 OR 37517-30-9 OR 62658
                 SEL RN
L22          376 S E4-24/CRN
L23          153 S L22 AND (MXS/CI OR MIX?)
L24          223 S L22 NOT L23
L25           83 S L24 NOT SALT
L26           79 S L25 NOT PMS/CI
L27          140 S L24 NOT L25
L28          219 S L26,L27
L29          157 S L22 NOT L28
L30            0 S L6 AND L14
L31            0 S L6 AND L22
L32            5 S C24H30O6/MF AND OC2-OC4-C5-C6-C6-C6/ES
                 SEL RN 1 3
L33            2 S E25-E26
L34            0 S E25-E26/CRN
L35            3 S L1,L33

     FILE 'HCAPLUS' ENTERED AT 07:58:57 ON 19 JAN 2005
L36          173 S L35
L37          196 S EPLERENONE
L38           19 S CGP30083 OR CGP()(30083 OR 30 083) OR EPOXYMEXRENONE
L39            8 S L6
L40            1 S L5
L41          213 S L36-L40
L42         2799 S L13
L43         3747 S METOPROLOL
L44            5 S BEATROLOL OR MEIJOPROLOL OR METOHEXAL OR SEROKEN OR SPESICOR
L45        18326 S L21
L46          605 S L19
L47           16 S L20
L48        20312 S L42-L47
L49        18326 S L21
L50         4320 S L28
L51           93 S L29
```

```
L52       15065 S ACEBUTOLOL OR ATENOLOL OR BISOPROLOL OR BOPINDOLOL OR BUCINDO
L53       26224 S L49-L52
L54        2038 S BETA ADRENERGIC ANTAGONIST
                E ADRENOCEPTOR/CT
L55        3381 S E17-E20
L56         137 S E32-E35 (L) ANTAGONIST
L57          15 S L41 AND L48
L58          14 S L41 AND L53
L59          17 S L41 AND L54-L56
L60          24 S L57-L59
L61           6 S L60 AND (PD<=20010727 OR PRD<=20010727 OR AD<=20010727)
L62           7 S L60 AND PHARMACIA?/PA,CS
L63           1 S L60 AND (ALEXANDER ? OR SCHUH ?)/AU
L64          12 S L61-L63
L65           6 S L61 AND L64

     FILE 'REGISTRY' ENTERED AT 08:13:26 ON 19 JAN 2005
L66           1 S 30236-31-8
L67           1 S "(S)-SOTALOL"/CN

     FILE 'HCAPLUS' ENTERED AT 08:14:33 ON 19 JAN 2005
L68         242 S L66,L67
L69       27097 S PROPRANOLOL
L70       39578 S L53,L68,L69
L71          14 S L41 AND L70
L72           0 S L71 NOT L60
L73          24 S L60,L71
L74           6 S L73 AND L61
L75           7 S L73 AND L62,L63
L76          12 S L74,L75
L77           7 S L76 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)
L78           5 S L76 NOT L77
L79          12 S L73 NOT L76

     FILE 'MEDLINE' ENTERED AT 08:17:39 ON 19 JAN 2005
L80           2 S L35
L81         200 S L37 OR L38
L82         200 S L80,L81
L83        3527 S L13
L84        4790 S L43 OR L44
L85       42726 S L21 OR L19 OR L20
L86         171 S L28 OR L29 OR L66 OR L67
L87       54921 S L52 OR L69
L88        1512 S L54
                E BETA ADRENERGIC ANTAGONIST/CT
                E E8+ALL
                E E2+ALL
L89       62846 S E14+NT
L90           8 S L82 AND L83-L89
L91           1 S L90 AND PY<=2001
L92           7 S L90 NOT L91

     FILE 'EMBASE' ENTERED AT 08:22:33 ON 19 JAN 2005
L93         430 S L82
L94      106403 S L83-L88
L95           9 S ADRENERGIC BETA ANTAGONIST
                E BETA ADRENERGIC ANTAGONIST/CT
                E E3+ALL
                E E2+ALL
L96      134943 S E6+NT
L97         190 S L93 AND L94-L96
L98           9 S L97 AND PY<=2001
L99           0 S EPLERENONE(L)CB/CT AND L98
```

```
     FILE 'BIOSIS' ENTERED AT 08:26:04 ON 19 JAN 2005
L100        182 S L82
L101         11 S L100 AND P/DT
L102         37 S L100 AND PY<=2001
L103          3 S L101,L102 AND (ALEXANDER ? OR SCHUH ?)/AU
L104         44 S L101,L102
L105          0 S L104 AND L83-L88,L95

=> fil biosis
FILE 'BIOSIS' ENTERED AT 08:28:33 ON 19 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 12 January 2005 (20050112/ED)

FILE RELOADED: 19 October 2003.

=> d l103 all tot

L103 ANSWER 1 OF 3  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation.  on STN
AN   2004:299139  BIOSIS
DN   PREV200400303820
TI   Methods of treating heart failure and hypertension using combinations of
     eplerenone and an angiotensin converting enzyme inhibitor.
AU   Perez, Alfonzo T. [Inventor, Reprint Author]; Asner, Debra J. [Inventor];
     LaChapelle, Richard J. [Inventor]; Alexander, John C.
     [Inventor]; Roniker, Barbara [Inventor]
CS   Princeton, NJ, USA
     ASSIGNEE: Pharmacia Corporation
PI   US 6747020 June 08, 2004
SO   Official Gazette of the United States Patent and Trademark Office Patents,
     (June 8 2004) Vol. 1283, No. 2. http://www.uspto.gov/web/menu/patdata.html
     . e-file.
     ISSN: 0098-1133 (ISSN print).
DT   Patent
LA   English
ED   Entered STN: 30 Jun 2004
     Last Updated on STN: 30 Jun 2004
AB   Methods of using eplerenone, an angiotensin converting enzyme
     inhibitor and optionally a diuretic are described for treatment of heart
     failure and hypertension.
NCL  514175000
CC   Pathology - Therapy   12512
     Cardiovascular system - Heart pathology   14506
     Cardiovascular system - Blood vessel pathology   14508
     Pharmacology - General   22002
     Pharmacology - Cardiovascular system   22010
     Allergy   35500
IT   Major Concepts
        Pharmacology
IT   Diseases
        heart failure: heart disease
        Heart Failure, Congestive (MeSH)
IT   Diseases
        hypertension: vascular disease
        Hypertension (MeSH)
IT   Chemicals & Biochemicals
          eplerenone: angiotensin-converting enzyme inhibitor-drug,
        cardiovascular-drug, enzyme inhibitor-drug
```

RN **107724-20-9 (eplerenone)**

L103 ANSWER 2 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1999:520742 BIOSIS
DN PREV199900520742
TI **Eplerenone**, a novel and selective aldosterone receptor antagonist: Efficacy in patients with mild to moderate hypertension.
AU Epstein, Murray [Reprint author]; Menard, Joel; **Alexander, John C.**; Roniker, Barbara
CS University Miami, Miami, FL, USA
SO Circulation, (Oct. 27, 1998) Vol. 98, No. 17 SUPPL., pp. I98-I99. print.
Meeting Info.: 71st Scientific Sessions of the American Heart Association. Dallas, Texas, USA. November 8-11, 1998. The American Heart Association.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Dec 1999
Last Updated on STN: 3 Dec 1999
CC Pharmacology - General 22002
Biochemistry studies - General 10060
Cardiovascular system - General and methods 14501
General biology - Symposia, transactions and proceedings 00520
IT Major Concepts
Cardiovascular Medicine (Human Medicine, Medical Sciences); Pharmacology
IT Diseases
hypertension: vascular disease
Hypertension (MeSH)
IT Chemicals & Biochemicals
aldosterone; **eplerenone**: antihypertensive-drug, aldosterone receptor antagonist, efficacy
IT Miscellaneous Descriptors
adverse events; blood pressure; target organ damage; Meeting Abstract
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
RN 52-39-1 (aldosterone)
107724-20-9 (eplerenone)

L103 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1999:25079 BIOSIS
DN PREV199900025079
TI **Eplerenone**, a new selective aldosterone receptor antagonist (SARA): Efficacy in patients with mild to moderate hypertension.
AU Epstein, M. [Reprint author]; **Alexander, J. C.**; Roniker, B.
CS Dep. Med., Univ. Miami Sch. Med., Miami, FL, USA
SO Journal of the American Society of Nephrology, (Sept., 1998) Vol. 9, No. PROGRAM AND ABSTR. ISSUE, pp. 322A-323A. print.
Meeting Info.: 31st Annual Meeting of the American Society of Nephrology. Philadelphia, Pennsylvania, USA. October 25-28, 1998. American Society of Nephrology.
CODEN: JASNEU. ISSN: 1046-6673.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 20 Jan 1999

Last Updated on STN: 20 Jan 1999
CC Pharmacology - Cardiovascular system 22010
Biochemistry studies - General 10060
Pathology - Therapy 12512
Cardiovascular system - Blood vessel pathology 14508
Pharmacology - Clinical pharmacology 22005
General biology - Symposia, transactions and proceedings 00520
IT Major Concepts
Cardiovascular Medicine (Human Medicine, Medical Sciences); Pharmacology
IT Diseases
hypertension: vascular disease
Hypertension (MeSH)
IT Chemicals & Biochemicals
eplerenone: antihypertensive-drug, selective aldosterone receptor antagonist
IT Miscellaneous Descriptors
Meeting Abstract; Meeting Poster
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
RN **107724-20-9 (eplerenone)**
52-39-1 (ALDOSTERONE)

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:28:39 ON 19 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Jan 2005 VOL 142 ISS 4
FILE LAST UPDATED: 18 Jan 2005 (20050118/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l77 all hitstr tot

L77 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:492701 HCAPLUS
DN 139:57968
ED Entered STN: 29 Jun 2003
TI Bretylium compositions and kits in preventing and treating cardiovascular conditions
IN Bacaner, Marvin B.; Kreevoy, Maurice M.

PA USA
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of U.S. Ser. No. 869,940.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-606
NCL 514161000
CC 63-6 (Pharmaceuticals)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003119794	A1	20030626	US 2002-271044	20021015 <--
	WO 2000040232	A2	20000713	WO 2000-US350	20000106 <--
	WO 2000040232	A3	20001123		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 2001005931	A	20030311	ZA 2001-5931	20010718 <--
	US 6482811	B1	20021119	US 2001-869940	20011127 <--
PRAI	US 1999-115143P	P	19990108 <--		
	US 1999-116567P	P	19990121 <--		
	WO 2000-US350	W	20000106 <--		
	US 2001-329447P	P	20011015 <--		
	US 2001-869940	A2	20011127 <--		
	US 2002-394953P	P	20020710		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003119794	ICM	A61K031-606
	NCL	514161000
US 2003119794	ECLA	A61K009/48H2; A61K045/06 <--
US 6482811	ECLA	A61K009/48H2; A61K045/06 <--

OS MARPAT 139:57968
AB The present invention is directed to pharmaceutical combinations and kits comprising bretylium as the active ingredient, as well as methods for preventing and/or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations. A resuscitation solution is prepared by dissolving bretylium tosylate 15, acetylsalicylic acid 7.5, and **esmolol** 0.25 mg, meglumine 0.3 mmol/kg, and potassium gluconate 2 mmol/dose in an aqueous solution of 5% glucose 70 mL. For producing a resuscitation solution suitable for administration to an average 70-kg human, the solution contains bretylium tosylate 1.05 g, acetylsalicylic acid 525, **esmolol** 17.5, meglumine 4095 and potassium gluconate 468 mg in 70 mL an aqueous solution of 5% glucose.
ST bretylium formulation cardiovascular disorder
IT Heart
(Purkinje system; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Disaccharides
Monosaccharides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Polysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminodeoxy; bretylium compns. and kits in preventing and treating

cardiovascular conditions)
IT Heart, disease
(angina pectoris; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Shock (circulatory collapse)
(antidefibrillatory; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(arrhythmia; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(atrial fibrillation; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Antihypotensives
Buffers
Cardiovascular agents
Heart, disease
Heart rate
Human
Partition
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(capsules; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Shock (circulatory collapse)
(cardiogenic; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Artery, disease
(coronary, spasm; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(failure; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Shock (circulatory collapse)
(hemorrhagic; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Shock (circulatory collapse)
(hypovolemic; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(infarction; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(injections, i.m.; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(injections, i.v.; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(injections; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(oral; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Shock (circulatory collapse)
(septic; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(solns.; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(suspensions; bretylium compns. and kits in preventing and treating

cardiovascular conditions)
IT Ganglion
(sympathetic, blockade; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(systole dysfunction; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Drug delivery systems
(tablets; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(tachycardia, atrial; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Antidepressants
(tricyclic; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(ventricular arrhythmia; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(ventricular fibrillation; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT Heart, disease
(ventricular tachycardia; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT **Adrenoceptor antagonists**
(β -; bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT 50-78-2, Acetylsalicylic acid 50-78-2D, Acetylsalicylic acid, salts 59-41-6, Bretylium 61-75-6, Bretylium tosylate **525-66-6, Propranolol**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT 3170-72-7P, Bretylium bromide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT 148794-29-0P, Bretylium dodecyl sulfate
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT 50-47-5, Desipramine 50-48-6, Amitriptyline 51-43-4, Epinephrine 54-21-7, Sodium salicylate 68-04-2, Sodium citrate 72-69-5, Nortriptyline 77-92-9, Citric acid, biological studies 144-55-8, Sodium bicarbonate, biological studies 438-60-8, Protriptyline 577-11-7, Sodium di(2-ethyl hexyl)sulfosuccinate 6284-40-8, Methyl glucamine 22232-71-9, Mazindol **26839-75-8, Timolol 29122-68-7, Atenolol 36894-69-6, Labetalol 37517-30-9, Acebutolol 51384-51-1, Metoprolol** 57460-41-0, Talinolol **72956-09-3, Carvedilol 81147-92-4, Esmolol 107724-20-9, Eplerenone** 282095-85-6 282095-86-7, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bretylium compns. and kits in preventing and treating cardiovascular conditions)
IT 151-21-3, SDS, reactions 598-56-1 3433-80-5, 2-Bromobenzyl bromide
RL: RCT (Reactant); RACT (Reactant or reagent)
(in bretylium salt preparation; bretylium compns. and kits in preventing and

treating cardiovascular conditions)

IT **525-66-6, Propranolol**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bretylium compns. and kits in preventing and treating cardiovascular conditions)

RN 525-66-6 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



IT **26839-75-8, Timolol 29122-68-7, Atenolol 36894-69-6, Labetalol 37517-30-9, Acebutolol 51384-51-1, Metoprolol 72956-09-3, Carvedilol 81147-92-4, Esmolol 107724-20-9, Eplerenone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bretylium compns. and kits in preventing and treating cardiovascular conditions)

RN 26839-75-8 HCAPLUS

CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 29122-68-7 HCAPLUS

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 36894-69-6 HCAPLUS

CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 37517-30-9 HCAPLUS
CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 51384-51-1 HCAPLUS
CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 72956-09-3 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 81147-92-4 HCAPLUS
CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:472394 HCAPLUS
DN 139:31256
ED Entered STN: 20 Jun 2003
TI Methods and compositions for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
IN Aiken, James W.
PA **Pharmacia Corporation, USA**
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-58
ICS A61K045-06; A61P027-02; A61P027-06
CC 2-4 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003049745	A1	20030619	WO 2002-US39807	20021212 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003158162	A1	20030821	US 2002-317650	20021212 <--
	EP 1455795	A1	20040915	EP 2002-784791	20021212 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014924	A	20041130	BR 2002-14924	20021212 <--
PRAI	US 2001-341033P	P	20011212 <--		
	WO 2002-US39807	W	20021212		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003049745	ICM	A61K031-58
	ICS	A61K045-06; A61P027-02; A61P027-06
US 2003158162	ECLA	A61K031/164+M; A61K031/5575+M; A61K031/58; A61K031/58+M; A61K031/585; A61K031/585+M; A61K045/06<--

AB A method for treating or preventing ophthalmic disorders comprising the

administration of one or more aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as **eplerenone** is disclosed. The method results in a reduction of intraocular pressure which treats or prevents the ophthalmic disorders. The epoxysteroid compds. can be co-administered with cytoskeletal disruptors, prostaglandin compds. and/or antiglaucoma agents. Among the disorders are intraocular hypertension, glaucoma, low tension glaucoma, age-related macula degeneration (AMD), macular edema, and diabetic retinopathy. As glucocorticoids and mineralocorticoids also cause the retention of ions, such as sodium and potassium, where aldosterone receptors are located, aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as **eplerenone** , also can be administered to modulate the intraocular concentration of ions. Thus, aldosterone receptor antagonists can be administered to maintain an intraocular ionic environment that is beneficial to intraocular cell survival.

ST epoxysteroid aldosterone receptor antagonist ophthalmic disorders treatment antiglaucoma

IT Epoxy group
(9,11-epoxy moiety-containing steroids; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Adenosine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(A3, antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(B; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Dopamine agonists
(D1; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(F; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Muscarinic agonists
(M3; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Muscarinic agonists
(M1; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Prostaglandins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PGD; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Somatostatin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSTR4, agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Tumor necrosis factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Corticosteroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Eye
(anterior chamber, aqueous humor inflow/outflow; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Eye
(aqueous humor, controlled inflow/outflow; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Anion exchangers
(chloride, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Eye, disease
(diabetic retinopathy; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxy-; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(epoxysteroidal antagonist; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrogen ion-sodium exchanger, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Eye
(intraocular fluid; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Glaucoma (disease)
(low-tension; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Eye, disease
(macula, senile degeneration; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Eye, disease
(macular edema; methods and compns. for treating ophthalmic disorders

with epoxy-steroidal aldosterone receptor antagonists)
IT Glaucoma (disease)
Human
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)
IT Adrenoceptor agonists
Antiglaucoma agents
Cholinergic agonists
Cholinergic antagonists
Muscarinic agonists
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT Cannabinoids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT Cytoskeleton
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prodrugs; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prostanoids; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)
IT Drug delivery systems
(solns., ophthalmic; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT Adrenoceptor antagonists
(α-; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT **Adrenoceptor antagonists**
(β -; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT **Adrenoceptor antagonists**
(β 2-; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I, II and IV inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)
IT 551-11-1, PGF2α

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT 11128-99-7, Angiotensin II
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT **26921-17-5**, **Timolol** maleate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in solution with dorzolamide hydrochloride; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 141436-78-4, Protein kinase C 182372-13-0, Rho kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for modulating intraocular ionic levels with epoxy-steroidal aldosterone receptor antagonists for treating ophthalmic disorders)

IT 95716-76-0 95716-78-2 95716-94-2 95716-95-3 95716-96-4
95716-97-5 95716-98-6 95716-99-7 95717-02-5 **107724-20-9**
380606-04-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT 51-43-4, Epinephrine 51-48-9, L-Thyroxine, biological studies 51-83-2, Carbachol 54-71-7, Pilocarpine hydrochloride 59-66-5, Acetazolamide 92-13-7, Pilocarpine 120-97-8, Dichlorophenamide 554-57-4, Methazolamide 4205-90-7, Clonidine **26839-75-8**, **Timolol** **27912-14-7**, Betagan **51781-21-6**, **Carteolol** hydrochloride 59803-98-4, Brimonidine **63659-18-7**, **Betaxolol** **63659-19-8**, **Betaxolol** hydrochloride 66711-21-5, Apraclonidine 94421-68-8, Anandamide 120279-96-1, Dorzolamide 130693-82-2, Dorzolamide hydrochloride 138890-62-7, Brinzolamide 150937-43-2 151499-39-7, Bafilomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT 120373-36-6, Unoprostone 130209-82-4, Latanoprost 155206-00-1, Lumigan 157283-68-6, Travoprost
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT 9000-83-3, ATPase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vacuolar proton, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Funder, J; WO 0195893 A 2001 HCAPLUS
(2) Grob, J; US 4559332 A 1985 HCAPLUS
(3) Mathur, L; WO 0187284 A 2001 HCAPLUS
(4) Olins, G; WO 9640255 A 1996 HCAPLUS
(5) Pharmacia Corp; WO 0209760 A 2002 HCAPLUS
(6) Rabasseda, X; DRUGS OF THE FUTURE 1999, V24(5), P488 HCAPLUS

IT **26921-17-5, Timolol** maleate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in solution with dorzolamide hydrochloride; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

RN 26921-17-5 HCAPLUS

CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 26839-75-8
CMF C13 H24 N4 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT **107724-20-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **26839-75-8, Timolol 27912-14-7**, Betagan
51781-21-6, Carteolol hydrochloride **63659-18-7**
, Betaxolol 63659-19-8, Betaxolol
hydrochloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

RN 26839-75-8 HCAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 27912-14-7 HCAPLUS
CN 1(2H)-Naphthalenone, 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 51781-21-6 HCAPLUS
CN 2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 63659-18-7 HCAPLUS
CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 63659-19-8 HCAPLUS
CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L77 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:396452 HCAPLUS
DN 138:363210
ED Entered STN: 23 May 2003
TI Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
IN Williams, Gordon H.; Funder, John W.; Garthwaite, Susan M.; Roniker, Barbara; Fedde, Kenton N.; Rocha, Ricardo
PA USA
SO U.S. Pat. Appl. Publ., 242 pp., Cont.-in-part of U.S. Ser. No. 713,348.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-58
NCL 514172000
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 1, 63, 75
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003096798	A1	20030522	US 2001-17288	20011213	<--
	US 2003125312	A1	20030703	US 2001-915784	20010726	<--
	US 6716829	B2	20040406			
	EP 1453522	A1	20040908	EP 2001-998044	20011213	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	US 2003191100	A1	20031009	US 2002-243876	20020913	<--
	US 2003203884	A1	20031030	US 2003-354823	20030130	<--
	US 2004067916	A1	20040408	US 2003-648863	20030826	<--
	US 2004102424	A1	20040527	US 2003-682527	20031009	<--
PRAI	US 1999-164390P	P	19991109	<--		
	US 2000-211064P	P	20000613	<--		
	US 2000-211250P	P	20000613	<--		
	US 2000-211253P	P	20000613	<--		
	US 2000-211264P	P	20000613	<--		
	US 2000-211311P	P	20000613	<--		
	US 2000-211340P	P	20000613	<--		
	US 2000-211451P	P	20000613	<--		
	US 2000-211459P	P	20000613	<--		
	US 2000-221358P	P	20000727	<--		
	US 2000-221364P	P	20000727	<--		
	US 2000-233056P	P	20000914	<--		
	US 2000-709253	A2	20001108	<--		
	US 2000-713348	A2	20001114	<--		
	US 2000-712543	A1	20001114	<--		
	US 2001-261352P	P	20010112	<--		
	US 2001-261497P	P	20010112	<--		
	US 2001-17288	B1	20011213	<--		
	WO 2001-US48419	W	20011213	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003096798	ICM	A61K031-58
	NCL	514172000
US 2004067916	ECLA	A61K031/00 <--
US 2004102424	ECLA	A61K031/00; A61K031/00+A; A61K031/415+M; A61K031/4152; A61K031/4152+M; A61K031/437; A61K031/437+M; A61K031/5513+M; A61K031/56+M; A61K031/57; A61K031/57+M; A61K031/58; A61K031/58+M; A61K001/585; A61K031/585+M; A61K045/06; A61K045/06+M <--

AB The present invention provides methods for the treatment or prophylaxis of

one or more aldosterone-mediated pathogenic effects in a subject suffering from or susceptible to the pathogenic effect or effects wherein the subject has one or more conditions selected from the group consisting of a sub-normal endogenous aldosterone level, salt sensitivity and an elevated dietary sodium intake. The methods comprise administering to the subject a therapeutically-effective amount of one or more epoxy-steroidal compds. that are aldosterone antagonists.

ST **eplerenone** epoxy steroid treatment aldosterone mediated disease hypertension

IT Human groups
(Japanese, American Indian, and Black ethnic groups; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects in various ethnic groups)

IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(albuminuria; antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)

IT Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Ion channel blockers
(calcium; **eplerenone** co-administration with a calcium channel blocker or a β-adrenoceptor blocker)

IT Drug delivery systems
(capsules; antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)

IT Cytoprotective agents
(cardioprotective; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Brain, disease
(cerebrovascular; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Menopause
(disorder, hot flash; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Baroreceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dysfunction; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Aging, animal
(elderly; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Blood vessel, disease
(endothelium, dysfunction; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Steroids, biological studies
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(epoxy-; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Heart, disease
(failure; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Heart, disease
(infarction; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT Heart, disease

(left ventricle, hypertrophy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Diuretics
(loop; treatment or prophylaxis of heart failure by administering an ACE inhibitor, a loop diuretic, and one or more epoxysteroidal compds.)
IT Kidney, disease
(nephrosclerosis; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Nerve, disease
(neuropathy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Diabetes mellitus
(non-insulin-dependent; antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)
IT Crystal structure
Crystallization
(of epoxysteroidal compds.; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Ovarian cycle
(premenstrual syndrome; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Size reduction
(preparation of amorphous **eplerenone** by comminution)
IT Freeze drying
(preparation of amorphous **eplerenone** by lyophilization)
IT Artery
(renal, renal arteriopathy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Hypertension
(renal; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Cytoprotective agents
(renoprotective; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Eye, disease
(retinopathy; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Brain, disease
(stroke; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Drug delivery systems
(tablets; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Antihypertensives
Antimigraine agents
Blood vessel, disease
Cardiovascular agents
Edema
Human
Kidney, disease
Liver, disease
Structure-activity relationship
(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)
IT Atherosclerosis
(use of epoxy-steroidal aldosterone antagonist to improve endothelial function in diet induced atherosclerosis)
IT **Adrenoceptor antagonists**

(β -; **eplerenone** co-administration with a calcium channel blocker or a β -adrenoceptor blocker)

IT 11128-99-7, Angiotensin II
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonist; co-administration of **eplerenone** with an ACE inhibitor or angiotensin II antagonist in patients with mild-moderate hypertension)

IT **107724-20-9DP**, **Eplerenone**, derivs.
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)

IT 88150-42-9, Amlodipine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of **eplerenone** and amlodipine in ambulatory blood pressure monitoring)

IT 114798-26-4, Losartan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of **eplerenone** and losartan in patients with low-renin hypertension)

IT 75847-73-3, Enalapril
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**eplerenone** and enalapril efficacy and safety in treating left ventricular hypertrophy and essential hypertension)

IT 192704-82-8 209253-73-6
RL: MSC (Miscellaneous)
(impurity mols.; crystallization of epoxysteroidal compds.)

IT 9015-82-1, Angiotensin-converting enzyme
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treatment or prophylaxis of heart failure by administering an ACE inhibitor, a loop diuretic, and one or more epoxysteroidal compds.)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT 7440-23-5, Sodium, biological studies 7647-14-5, Sodium chloride, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(salt sensitivity; use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT 64-17-5, Ethanol, biological studies 67-56-1, Methanol, biological studies 75-05-8, Acetonitrile, biological studies 78-93-3, Methyl ethyl ketone, biological studies 98-95-3, Nitrobenzene, biological studies 100-41-4, Ethyl benzene, biological studies 141-78-6, Ethyl acetate, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(solvent; crystallization of epoxysteroidal compds.)

IT 52-39-1, Aldosterone
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT **107724-20-9P**, **Eplerenone**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); PUR (Purification or

recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT 95716-76-0P 95716-78-2P 95716-94-2P 95716-95-3P 95716-96-4P
95716-97-5P 95716-98-6P 95716-99-7P 95717-02-5P 380606-04-2P
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

IT **107724-20-9DP**, **Eplerenone**, derivs.
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(antihypertensive, renal, and metabolic effects of **eplerenone** and enalapril in patients with type 2 diabetes, albuminuria, and hypertension)

RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **107724-20-9P**, **Eplerenone**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of epoxy-steroidal aldosterone antagonist for treatment or prophylaxis of aldosterone-mediated pathogenic effects)

RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:319257 HCAPLUS
DN 138:343856
ED Entered STN: 25 Apr 2003
TI Buccal sprays or capsules containing cardiovascular or renal drugs
IN Dugger, Harry A.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K009-00
ICS A61L009-04
NCL 424043000
CC 63-6 (Pharmaceuticals)
FAN.CNT 16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003077229	A1	20030424	US 2002-230075	20020829 <--
	WO 9916417	A1	19990408	WO 1997-US17899	19971001 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	EP 1029536	A1	20000823	EP 2000-109347	19971001 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1036561	A1	20000920	EP 2000-109357	19971001 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2004019909	A2	20040311	WO 2003-US26853	20030827
	WO 2004019909	A3	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI WO 1997-US17899 A2 19971001 <--
US 2000-537118 A2 20000329 <--
EP 1997-911621 A3 19971001 <--
US 2002-230075 A 20020829

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003077229	ICM	A61K009-00
	ICS	A61L009-04
	NCL	424043000
US 2003077229	ECLA	A61K009/00M18D; A61K009/00M20B; A61K031/085; A61K031/137; A61K031/138; A61K031/197; A61K031/27; A61K003/4178; A61K031/421; A61K031/433; A61K031/7076<--
WO 9916417	ECLA	A61K009/00M18D; A61K009/00M20B <--
EP 1029536	ECLA	A61K009/00M20B <--
EP 1036561	ECLA	A61K009/00M20B <--

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a polar lingual spray contained isoproterenol-HCl 0.5-6, water 50-75, EtOH 5-10, PEG 5-15, sorbitol 0.4-1.0, aspartame 0.04-0.1, and flavors 2-3%.

ST cardiovascular drug buccal spray; renal drug capsule

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C2-24; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C2-8; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Alcohols, biological studies
Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C7-18; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Drug delivery systems
(aerosols, sprays; buccal sprays or capsules containing cardiovascular or renal drugs)

IT Antianginal agents
Antiarrhythmics
Anticoagulants
Antihypertensives
Antihypotensives
Cardiovascular agents
Flavor
Polar solvents
Propellants (sprays and foams)
Sweetening agents
Vasodilators
(buccal sprays or capsules containing cardiovascular or renal drugs)

IT Esters, biological studies
Glycerides, biological studies
Pentosans
Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal sprays or capsules containing cardiovascular or renal drugs)

IT Drug delivery systems
(buccal; buccal sprays or capsules containing cardiovascular or renal

drugs)
IT Drug delivery systems
(capsules; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citrus; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Heart, disease
(failure; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Flavoring materials
(fruit flavors; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Mucopolysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heparinoids; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormones; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Mouth
(mucosa; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Drug delivery systems
(mucosal; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric, C2-8; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Heart
(regulators for; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spearmint; buccal sprays or capsules containing cardiovascular or renal drugs)
IT Drug delivery systems
(sprays; buccal sprays or capsules containing cardiovascular or renal drugs)
IT 9005-49-6, Heparin, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SNAC/SNAD; buccal sprays or capsules containing cardiovascular or renal drugs)
IT 50-78-2, Aspirin 51-06-9, Procainamide 51-30-9, Isoproterenol hydrochloride 54-31-9, Furosemide 56-54-2, Quinidine 57-41-0, Phenytoin 58-00-4, Apomorphine 58-32-2, Dipyridamole 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 59-41-6, Bretylium 60-87-7, Promethazine 64-17-5, Ethanol, biological studies 65-28-1, Phentolamine mesylate 71-63-6, Digitoxin 74-98-6, Propane, biological studies 75-28-5, Iso-butane 78-11-5, Pentaerythritol tetranitrate 78-78-4, Iso-pentane 81-81-2, Warfarin 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate

89-25-8, Edaravone 106-97-8, N-Butane, biological studies 109-66-0, N-Pentane, biological studies 114-07-8, Erythromycin 127-31-1, Fludrocortisone 137-58-6, Lidocaine 147-24-0, DiPhenhydramine hydrochloride 303-53-7, Cyclobenzaprine 364-98-7, Diazoxide 463-04-7, Amyl nitrite 463-82-1, Neo-pentane 523-87-5, Dimenhydrinate **525-66-6**, **Propranolol** 541-15-1, Carnitine 555-30-6, Methyldopa 569-65-3, Meclizine 630-93-3, Phenytoin sodium 745-65-3, Alprostadil 1951-25-3, Amiodarone 3239-44-9, Dexfenfluramine 3737-09-5, Disopyramide **3930-20-9**, **Sotalol** 4205-90-7, Clonidine 5786-21-0, Clozapine 6493-05-6, Pentoxifylline 7297-25-8, Erythrityl tetranitrate 9041-08-1 10238-21-8, Glyburide **13523-86-9**, **Pindolol** 15078-28-1, Nitroprusside 19216-56-9, Prazosin 20830-75-5, Digoxin 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 25322-68-3, Polyethylene glycol 25717-80-0, Molsidomine 28395-03-1, Bumetanide 29110-47-2, Guanfacine **29122-68-7**, **Atenolol** **30236-31-8**, D-**Sotalol** 30516-87-1, Zidovudine 31329-57-4, Naftidrofuryl 31828-71-4, Mexiletine 34368-04-2, Dobutamine 35700-23-3, Carboprost **36894-69-6**, **Labetalol** 37270-89-6, Nadroparin calcium **37517-30-9**, **Acebutolol** 38304-91-5, Minoxidil 39562-70-4, Nitrendipine 41708-72-9, Tocainide **42200-33-9**, **Nadolol** 42399-41-7, Diltiazem 42794-76-3, Midodrine 47931-85-1, Salmon calcitonin 49562-28-9, Fenofibrate **51384-51-1**, **Metoprolol** 54063-53-5, Propafenone 54143-55-4, Flecainide 55142-85-3, Ticlopidine 55837-25-7, Buflomedil 55985-32-5, Nicardipine 56211-40-6, Torsemide **56980-93-9**, **Celiprolol** 62571-86-2, Captopril 63590-64-7, Terazosin **63659-18-7**, **Betaxolol** 63675-72-9, Nisoldipine 64706-54-3, Bepridil 65141-46-0, Nicorandil 66085-59-4, Nimodipine **66722-44-9**, **Bisoprolol** 67227-56-9, Fenoldopam 70059-30-2, Cimetidine hydrochloride 72509-76-3, Felodipine **72956-09-3**, **Carvedilol** 73963-72-1, Cilostazol 74191-85-8, Doxazosin 74863-84-6, Argatroban 75438-57-2, Moxonidine 75695-93-1, Isradipine 75847-73-3, Enalapril 76547-98-3, Lisinopril 76824-35-6, Famotidine 78415-72-2, Milrinone 78919-13-8, Iloprost 79517-01-4, Octreotide acetate **81147-92-4**, **Esmolol** 81403-80-7, Alfuzosin 82956-11-4, Nafamostat mesilate 83647-97-6, Spirapril 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88069-67-4, Pilsicainide 88150-42-9, Amlodipine 88768-40-5, Cilazapril 89226-50-6, Manidipine 89371-37-9, Imidapril 93107-08-5, Ciprofloxacin hydrochloride 95635-55-5, Ranolazine 98048-97-6, Fosinopril 99614-01-4, Ondansetron hydrochloride 100427-26-7, Lercanidipine 103628-48-4, Sumatriptan succinate 103775-10-6, Moexipril 104713-75-9, Barnidipine 104993-28-4, Fondaparinux 106133-20-4, Tamsulosin 107133-36-8, Perindopril erbumine **107724-20-9**, **Eplerenone** 110101-66-1, Tirilazad 113665-84-2, Clopidogrel 114798-26-4, Losartan 115256-11-6, Dofetilide 116308-55-5, Vatanidipine 120993-53-5, Desirudin 125926-17-2, Sarpogrelate 128270-60-0, Bivalirudin 133040-01-4, Eprosartan 133107-64-9, Insulin lispro 137862-53-4, Valsartan 138068-37-8, Lepirudin 138402-11-6, Irbesartan 139481-59-7, Candesartan 139755-83-2, Sildenafil 141505-33-1, Levosimendan 143653-53-6, Abciximab 144494-65-5, Tirofiban 144701-48-4, Telmisartan 147536-97-8, Bosentan 159138-80-4, Cariporide 159776-70-2, Melagatran 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 168626-94-6, YM087 171596-29-5, Tadalafil 180384-57-0, Tezosentan 188627-80-7, Eptifibatide 192939-46-1, H376/95 224785-90-4, Vardenafil 516482-86-3, Sermorelin acetate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal sprays or capsules containing cardiovascular or renal drugs)

IT **525-66-6**, **Propranolol** **3930-20-9**, **Sotalol** **13523-86-9**, **Pindolol**

29122-68-7, Atenolol 30236-31-8, D-Sotalol 36894-69-6, Labetalol 37517-30-9, Acebutolol 42200-33-9, Nadolol 51384-51-1, Metoprolol 56980-93-9, Celiprolol 63659-18-7, Betaxolol 66722-44-9, Bisoprolol 72956-09-3, Carvedilol 81147-92-4, Esmolol 107724-20-9, Eplerenone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal sprays or capsules containing cardiovascular or renal drugs)

RN 525-66-6 HCAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 3930-20-9 HCAPLUS
CN Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 13523-86-9 HCAPLUS
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 30236-31-8 HCAPLUS
CN Methanesulfonamide, N-[4-[(1R)-1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 36894-69-6 HCAPLUS
CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 37517-30-9 HCAPLUS
CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 42200-33-9 HCAPLUS

CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 51384-51-1 HCAPLUS
CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 56980-93-9 HCAPLUS
CN Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 63659-18-7 HCAPLUS
CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 66722-44-9 HCAPLUS
CN 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 72956-09-3 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 81147-92-4 HCAPLUS
CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-,
methyl ester (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:755214 HCAPLUS
DN 137:263024
ED Entered STN: 04 Oct 2002
TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
IN Murugesan, Natesan; Tellew, John E.; Macor, Jhon E.; Gu, Zhengxiang
PA Bristol-Myers Squibb Co., USA
SO U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-4166
ICS A61K031-4184; A61K031-4196; C07D233-32; C07D213-68; C07D215-233; C07D249-08
NCL 514258000
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002143024	A1	20021003	US 2000-737201	20001214 <--
	US 6638937	B2	20031028		
	US 2004106833	A1	20040603	US 2003-673100	20030926 <--
	US 6835741	B2	20041228		
	US 2004127515	A1	20040701	US 2003-672572	20030926 <--
PRAI	US 1998-91847P	P	19980706 <--		

US 1999-345392	B2	19990701	<--
US 1999-464037	B2	19991215	<--
US 2000-481197	B2	20000111	<--
US 2000-513779	A2	20000225	<--
US 2000-604322	A2	20000626	<--
US 2000-643640	B2	20000822	<--
US 2000-737201	A3	20001214	<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002143024	ICM	A61K031-4166
	ICS	A61K031-4184; A61K031-4196; C07D233-32; C07D213-68; C07D215-233; C07D249-08
	NCL	514258000
US 2002143024	ECLA	C07D261/16; C07D413/14+261+249B+207; C07D413/14+261+213+207; C07D413/14+261+261+235; C07D413/14261+241B+235; C07D413/14+261+235+233; C07D413/14+261+235+213; C07D413/14+261+235+207; C07D413/1+333B+261+235; C07D417/14+285B+261+235; C07D471/04+239B+221B; C07D471/04+235B+221B; C07D487/04+49C+231C; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+249B; C07D413/12+261+239; C07D413/12+261+231; C07D413/12+261+213; C07D413/12+261+235C; C07D413/12+261+233; C07D413/12+26+215; C07D413/12+261+235; C07D413/12+271+261; C07D413/12+307B+261 <--
US 2004106833	ECLA	C07D261/16; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+213; C07D413/12+261+215; C07D413/12+261+231; C07D413/12+261+233; C07D413/12+261+235; C07D413/12+261+235C; C07D413/12+21+239; C07D413/12+261+249B; C07D413/12+271+261; C07D413/12+307B+261; C07D413/14+261+213+207; C07D413/14+261+235+213; C07D413/14+261+235+233; C07D413/14+261+241B+235; C07D413/14+261+261+235; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/04+235B+221B; C07D471/04+239B+221B; C07D487/04+249C+231C <--
US 2004127515	ECLA	C07D261/16; C07D413/14+261+235+207; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/0+239B+221B; C07D471/04+235B+221B; C07D487/04+249C+231C; C07D401/12+231+215; C07D403/14+241B+235207; C07D413/12+261+249B; C07D413/12+261+239; C07D413/12+261+231; C07D413/12+261+213; C07D413/2+261+235C; C07D413/12+261+233; C07D413/12+261+215; C07D413/12+261+235; C07D413/12+271+261; C07D413/14+261+249B+207; C07D413/14+261+213+207; C07D413/14+261+261+235; C07D013/14+261+241B+235; C07D413/14+261+235+233; C07D413/14+261+235+213 <--

OS MARPAT 137:263024

GI



I

AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyloxy, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano, OH, hydroxyalkyl, NO2, etc; with provisos) were prepared as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl derivative (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.

ST isoxazolyl biphenylsulfonamide prepn angiotensin endothelin receptor antagonist; diazaspirononenylmethyldimethylisoxazolylbiphenylsulfonamide prepn angiotensin endothelin receptor antagonist; antihypertensive biphenylsulfonamide prepn

IT Angiotensin receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(angiotensin II, antagonists; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Endothelin receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(antagonists; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Prostate gland, disease
(benign hyperplasia, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Meninges
(disease, subarachnoid hemorrhage, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Sexual behavior
(disorder, treatment of female; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and

endothelin receptor antagonists)

IT Heart, disease
Kidney, disease
(failure, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Sexual behavior
(impotence, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Antiasthmatics
Antihypertensives
Antimigraine agents
Antitumor agents
Human
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Growth inhibitors, animal
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Artery, disease
(restenosis, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Atherosclerosis
Endotoxemia
Hypertension
Ischemia
(treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 62571-86-2, Captopril 74258-86-9, Alacepril 75847-73-3, Enalapril 76547-98-3, Lisinopril 81872-10-8, Zofenopril 82924-03-6, Pentopril 83435-66-9, Delapril 85441-61-8, Quinapril 87333-19-5, Ramipril 98048-97-6, Fosinopril 111223-26-8, Ceranapril 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254737-84-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254737-85-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methylamino)methyl]- 254737-86-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl- 254737-87-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254737-88-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254737-89-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-pyrazinyl- 254737-90-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3-chloropyrazinyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254737-91-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254737-92-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-

dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3,6-dimethylpyrazinyl)-
254737-94-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-
pyrrolidinyl)methyl]-N-(3-methoxypyrazinyl)- 254737-96-7P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-formyl- 254737-98-9P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-oxo-1-
pyrrolidinyl)methyl]- 254738-00-6P, Pentanamide, N-[[2'-[[(3,4-dimethyl-
5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-
1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- 254738-03-9P,
[1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-
dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-
imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-05-1P, [1,1'-Biphenyl]-2-
sulfonamide, 4'-[[2-(2-methoxyethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-
yl]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-06-2P,
[1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-
(ethoxymethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-
254738-07-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-
4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-
1-pyrrolidinyl)methyl]- 254738-09-5P, [1,1'-Biphenyl]-2-sulfonamide,
N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]-
254738-10-8P, Pentanamide, N-[[2'-[[(3-methyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-
[(methylamino)carbonyl]propyl]- 254738-11-9P, Pentanamide,
N-[[2'-[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-
yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]-
254738-12-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-
propyl- 254738-13-1P, 1H-Benzimidazole-7-carboxylic acid,
1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-
yl]methyl]-2-ethoxy-, methyl ester 254738-14-2P, 1H-Benzimidazole-7-
carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-4-yl]methyl]-2-ethoxy- 254738-15-3P, 1H-Benzimidazole-7-
carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254738-16-4P,
1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-
254738-17-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-
pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-,methylester
254738-18-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-
pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254738-19-7P,
1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-
pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-
254738-20-0P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-
pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-
254738-21-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-
quinolinyl)oxy]methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)- 254738-22-2P
, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-
imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-23-3P,
1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, methyl
ester 254738-24-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N,N-
dimethyl-2-propyl- 254738-25-5P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-
dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)- 254738-26-6P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-

en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-
254738-27-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-
methoxyethyl)- 254738-28-8P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-
dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3-methoxy-5-methylpyrazinyl)-
254738-29-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4-bromo-3-methyl-5-
isoxazolyl)-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-
[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254738-30-2P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-
[(formylmethylamino)methyl]- 254738-31-3P, Propanamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-32-4P, Cyclopropanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-33-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-N,2-dimethyl- 254738-34-6P, Butanamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-35-7P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254738-36-8P, 4-Pentynamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-37-9P, Cyclobutanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-38-0P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-N,3-dimethyl- 254738-39-1P, Propanamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2,2-
trimethyl- 254738-40-4P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-methoxy-N-methyl-
254738-41-5P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-
3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-2-ethoxy-N-methyl- 254738-42-6P,
2-Furancarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-
yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-
2-yl]methyl]-N-methyl- 254738-43-7P, Pentanamide, N-[[4-[(2-butyl-4-oxo-
1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,4-dimethyl-
254738-44-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-
3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-N-methyl- 254738-45-9P, 3-Thiophenecarboxamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-46-0P, Cyclopentaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-47-1P, Cyclohexanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-48-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-
3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-N,3-dimethyl- 254738-49-3P, Benzeneacetamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-
dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254738-50-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-

en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254738-51-7P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254738-52-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254738-53-9P, Cyclohexaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-54-0P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254738-55-1P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254738-56-2P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254738-57-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(dimethylamino)carbonyl]methylamino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-58-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[[(1,1-dimethylethyl)amino]carbonyl]methylamino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-59-5P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, ethyl ester 254738-60-8P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 2-methylpropyl ester 254738-61-9P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254738-62-0P, 2-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-63-1P, 3-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-64-2P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-65-3P, 1H-Pyrrole-2-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,1-dimethyl- 254738-66-4P, 1,2,3-Thiadiazole-4-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-67-5P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl- 254738-68-6P, 4-Isoxazolecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,5-trimethyl- 254738-69-7P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254738-70-0P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl- 254738-71-1P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-cyano-N-methyl- 254738-72-2P, Benzamide,

N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-cyano-N-methyl- 254738-73-3P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254738-74-4P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-chloro-N-methyl- 254738-75-5P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-chloro-N-methyl- 254738-76-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-chloro-N-methyl- 254738-78-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2,3-difluoro-N-methyl- 254738-79-9P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,4-difluoro-N-methyl- 254738-80-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,5-difluoro-N-methyl- 254738-81-3P, Benzamide, 4-acetyl-N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-82-4P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-ethoxy-N-methyl- 254738-83-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-84-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(propylsulfonyl)amino]- 254738-85-7P, L-Valine, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, methyl ester 254738-86-8P, L-Valine, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- 254738-87-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(4-oxo-2-propyl-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254738-88-0P, Butanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254738-89-1P, Pentanamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254738-90-4P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-91-5P, Pentanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254738-92-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254738-93-7P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]- 254738-94-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254738-95-9P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-, methyl ester 254738-96-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(methoxymethyl)- 254738-97-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro- 254738-98-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-

3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-99-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)- 254739-00-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)- 254739-01-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-methyl- 254739-02-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254739-03-2P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-04-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254739-05-4P, Benzeneacetamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]- 254739-06-5P, Butanamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]-3,3-dimethyl-
254739-07-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-amino-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-08-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-nitro- 254739-09-8P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-10-1P, Cyclopropanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-11-2P, Benzenepropanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-12-3P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-13-4P, Hexanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-14-5P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-15-6P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,4-dimethyl-, (2S)- 254739-16-7P, Cyclopropanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-17-8P, Benzenepropanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-18-9P, Benzeneacetamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-19-0P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254739-20-3P, Hexanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-21-4P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254739-22-5P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S)- 254739-23-6P, Cyclopropanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-24-7P, Benzenepropanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-

[(methylamino)carbonyl]propyl]- 254739-25-8P, Benzeneacetamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-26-9P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-27-0P, Hexanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-28-1P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-29-2P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]- 254739-30-5P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(hexylamino)carbonyl]-2-methylpropyl]- 254739-31-6P, Pentanamide, N-[[2-cyano-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-32-7P, Pentanamide, N-[[2-(cyanomethyl)-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-33-8P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]- 254739-34-9P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N,N-dimethyl- 254739-35-0P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-methyl- 254739-36-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(methoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-37-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- 254739-38-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-methyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-39-4P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-40-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-42-9P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-fluoro[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-43-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(phenoxymethyl)- 254739-44-1P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(1H-pyrazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-45-2P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-46-3P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)- 254739-47-4P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]- 254739-48-5P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-,(2S) 254739-49-6P, Pentanamide, N-[[2-chloro-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-50-9P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-

[(methylamino)carbonyl]propyl]- 254739-51-0P, Cyclobutanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-52-1P, 1H-Imidazole-5-carboxylic acid, 1-[[2-chloro-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254739-53-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methylsulfonyl)amino]- 254739-54-3P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(4-methyl-1-piperazinyl)carbonyl]propyl]- 254739-55-4P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(1-piperidinylcarbonyl)propyl]- 254739-56-5P, Pentanamide, N-[(1S)-1-[[(3,3-dimethylbutyl)amino]carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-57-6P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-methylpropyl]- 254739-58-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(1-methylethoxy)methyl]-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254739-59-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(propoxymethyl)- 254739-60-1P, 1H-Imidazole-5-carboxamide, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254739-61-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-62-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-oxo-1(2H)-pyridinyl)methyl]- 254739-63-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1H-pyrazol-1-ylmethyl)- 254739-64-5P, 1H-Imidazole-5-carboxamide, 2-butyl-4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-65-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-methyl-4-quinolinyl)oxy]methyl]- 254739-66-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-67-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-68-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- 254739-69-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-70-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-71-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-72-5P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- 254739-73-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254739-74-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254739-75-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-

yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254739-76-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254739-77-0P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-79-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-80-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254739-81-6P, 1H-Imidazole-5-carboxamide, 1-[[2-chloro-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254739-82-7P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254739-83-8P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254739-84-9P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254739-85-0P, 3-Pyridinecarboxylic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- 254739-86-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-87-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-88-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-89-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-6-[[[methyl(1-methylethyl)amino]carbonyl]amino]-4-oxo-3(4H)-quinazolinyl]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-90-7P, 3-Pyridinecarboxamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- 254739-91-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254739-92-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254739-93-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-94-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- 254739-95-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-4-methyl- 254739-96-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-3(4H)-quinazolinyl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-97-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254739-98-5P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-99-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(4,4-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254740-00-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254740-01-7P, Acetamide, N-[2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- 254740-02-8P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester 254740-03-9P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-

yl]methyl]-N-[(1S)-2-methyl-1-[(propylamino)carbonyl]propyl]-
254740-04-0P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-
[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]propyl]- 254740-05-1P,
[1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-
[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254740-06-2P, [1,1'-Biphenyl]-2-
sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-
quinolinyl)oxy]methyl]-2'-(trifluoromethyl)- 254740-07-3P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)- 254740-08-4P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-methylpropoxy)methyl]-
254740-09-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-
[(ethylsulfonyl)amino]- 254740-10-8P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-
dimethyl-5-isoxazolyl)-2'-[(2,2,2-trifluoroethoxy)methyl]- 254740-11-9P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-
254740-12-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-
2'-(ethoxymethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-
254740-15-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-
2'-(ethoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-
cycloheptimidazolyl)methyl]- 254740-18-6P, [1,1'-Biphenyl]-2-
sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-
(3,4-dimethyl-5-isoxazolyl)-2'-(3,3,3-trifluoropropyl)- 254740-20-0P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)-
254740-21-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(1,1-difluoroethyl)-N-(3,4-
dimethyl-5-isoxazolyl)- 254740-22-2P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-
dimethyl-5-isoxazolyl)-2'-(2,2,2-trifluoroethyl)- 254740-23-3P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-methylpropoxy)-
254740-24-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-
methoxyethoxy)- 254740-25-5P, [1,1'-Biphenyl]-2-sulfonamide,
2'-butyl-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-
(3,4-dimethyl-5-isoxazolyl)- 254740-26-6P, [1,1'-Biphenyl]-2-
sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-
(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254740-27-7P,
[1,1'-Biphenyl]-2-sulfonamide, N-(4-bromo-3-methyl-5-isoxazolyl)-4'-[(2-
butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(trifluoromethyl)-
254740-28-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4-chloro-3-methyl-5-isoxazolyl)-2'-
(trifluoromethyl)- 254740-29-9P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-
dimethyl-5-isoxazolyl)-2'-[(methoxymethylamino)methyl]- 254740-30-2P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-[(2,2-difluoroethoxy)methyl]-N-(3,4-dimethyl-5-
isoxazolyl)- 254740-31-3P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-
dimethyl-5-isoxazolyl)-2'-(2-fluoroethyl)- 254740-32-4P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-hydroxyethyl)-
254740-33-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-
methylbutyl)- 254740-34-6P, [1,1'-Biphenyl]-2-sulfonamide,
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-
dimethyl-5-isoxazolyl)-2'-(2-methylpropyl)- 254740-35-7P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(3,3-difluorobutyl)-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-

(ethoxymethyl)- 254740-36-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)- 254740-37-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254740-38-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254740-39-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254740-40-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254740-41-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254740-42-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methylamino)methyl]- 254740-43-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254740-44-8P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- 254740-45-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254740-46-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-(2-methoxyethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254740-47-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-(ethoxymethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254740-48-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254740-49-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254740-50-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl- 254740-51-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254740-52-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254740-53-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254740-54-0P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- 254740-55-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-,methylester 254740-56-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254740-57-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254740-58-4P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254740-59-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-N-(3-methyl-5-isoxazolyl)- 254740-60-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-61-9P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(4,5-dimethyl-3-

isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, methyl ester 254740-62-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N,N-dimethyl-2-propyl- 254740-63-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(hydroxymethyl)- 254740-64-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)- 254740-65-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methoxyethyl)- 254740-66-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(formylmethylamino)methyl]- 254740-67-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-68-6P, Cyclopropanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-69-7P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2-dimethyl- 254740-70-0P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-71-1P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254740-72-2P, 4-Pentynamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-73-3P, Cyclobutanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-74-4P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254740-75-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2,2-trimethyl- 254740-76-6P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-methoxy-N-methyl- 254740-77-7P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-ethoxy-N-methyl- 254740-78-8P, 2-Furancarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-79-9P, Pentanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,4-dimethyl- 254740-80-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-81-3P, 3-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-82-4P, Cyclopentaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-83-5P, Cyclohexanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-84-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254740-85-7P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-

254740-86-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254740-87-9P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254740-88-0P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254740-89-1P, Cyclohexaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-90-4P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254740-91-5P

, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254740-92-6P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254740-93-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(dimethylamino)carbonyl]methylamino]methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-94-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[[(1,1-dimethylethyl)amino]carbonyl]methylamino]methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-95-9P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, ethyl ester 254740-96-0P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 2-methylpropyl ester 254740-97-1P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254740-98-2P, 2-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-99-3P, 3-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254741-00-9P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254741-01-0P, 1H-Pyrrole-2-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,1-dimethyl- 254741-02-1P, 1,2,3-Thiadiazole-4-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254741-03-2P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl- 254741-04-3P, 4-Isoxazolecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,5-trimethyl- 254741-05-4P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254741-06-5P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl- 254741-07-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-

biphenyl]-2-yl]methyl]-3-cyano-N-methyl- 254741-08-7P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-cyano-N-methyl- 254741-09-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254741-10-1P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-chloro-N-methyl- 254741-11-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-chloro-N-methyl- 254741-12-3P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-chloro-N-methyl- 254741-13-4P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2,3-difluoro-N-methyl- 254741-14-5P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,4-difluoro-N-methyl- 254741-15-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,5-difluoro-N-methyl- 254741-16-7P, Benzamide, 4-acetyl-N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254741-17-8P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-ethoxy-N-methyl- 254741-19-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(propylsulfonyl)amino]- 254741-20-3P, L-Valine, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, methyl ester 254741-22-5P, L-Valine, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- 254741-24-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(4-oxo-2-propyl-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254741-26-9P, Butanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254741-27-0P, Pentanamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254741-28-1P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-30-5P, Pentanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254741-31-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254741-32-7P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]- 254741-33-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(trifluoromethyl)- 254741-34-9P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-, methyl ester 254741-35-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(methoxymethyl)- 254741-36-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-fluoro- 254741-37-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254741-38-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)- 254741-39-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)- 254741-40-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-methyl- 254741-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254741-42-9P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-43-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254741-44-1P, Benzeneacetamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]- 254741-45-2P, Butanamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]-3,3-dimethyl- 254741-46-3P, [1,1'-Biphenyl]-2-sulfonamide, 2'-amino-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254741-48-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-nitro- 254741-50-9P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-52-1P, Cyclopropanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-54-3P, Benzenepropanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-56-5P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-58-7P, Hexanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-60-1P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-62-3P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,4-dimethyl-, (2S)- 254741-64-5P, Cyclopropanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-66-7P, Benzenepropanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-68-9P, Benzeneacetamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-70-3P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254741-72-5P, Hexanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-74-7P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254741-76-9P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S)- 254741-78-1P, Cyclopropanecarboxamide,

N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-80-5P, Benzenepropanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-82-7P, Benzeneacetamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-85-0P, Butanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-methyl-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-87-2P, Hexanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-89-4P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254741-91-8P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]- 254741-93-0P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(hexylamino)carbonyl]-2-methylpropyl]- 254741-95-2P, Pentanamide, N-[[2-cyano-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-97-4P, Pentanamide, N-[[2-(cyanomethyl)-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-99-6P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]- 254742-01-3P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-N,N-dimethyl- 254742-03-5P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-N-methyl- 254742-05-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(methoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-06-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- 254742-07-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-methyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-08-0P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254742-09-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(hydroxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-10-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-11-5P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-fluoro[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254742-12-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(phenoxymethyl)- 254742-13-7P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(1H-pyrazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254742-14-8P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254742-15-9P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)- 254742-16-0P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]- 254742-17-1P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-,(2S) 254742-18-2P, Pentanamide, N-[[2-chloro-2'-[[(4,5-

dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-19-3P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-20-6P, Cyclobutanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-21-7P, 1H-Imidazole-5-carboxylic acid, 1-[[2-chloro-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254742-22-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methylsulfonyl)amino]- 254742-23-9P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(4-methyl-1-piperazinyl)carbonyl]propyl]- 254742-24-0P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(1-piperidinylcarbonyl)propyl]- 254742-25-1P, Pentanamide, N-[(1S)-1-[[(3,3-dimethylbutyl)amino]carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254742-28-4P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-methylpropyl]- 254742-29-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(1-methylethoxy)methyl]- 254742-31-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(propoxymethyl)- 254742-33-1P, 1H-Imidazole-5-carboxamide, 4-chloro-1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254742-35-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-fluoro-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-36-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-oxo-1(2H)-pyridinyl)methyl]- 254742-37-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1H-pyrazol-1-ylmethyl)- 254742-38-6P, 1H-Imidazole-5-carboxamide, 2-butyl-4-chloro-1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254742-39-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-methyl-4-quinolinyl)oxy]methyl]- 254742-41-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-43-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-45-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- 254742-46-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-47-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-49-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-51-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- 254742-53-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254742-54-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254742-56-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254742-58-0P,

1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254742-60-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-62-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-64-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254742-65-9P, 1H-Imidazole-5-carboxamide, 1-[[2-chloro-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254742-66-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254742-67-1P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254742-68-2P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254742-69-3P, 3-Pyridinecarboxylic acid, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- 254742-70-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-71-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-72-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-73-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-6-[[[methyl(1-methylethyl)amino]carbonyl]amino]-4-oxo-3(4H)-quinazolinyl]methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-75-1P, 3-Pyridinecarboxamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- 254742-76-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-77-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-78-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-79-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- 254742-80-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-4-methyl- 254742-81-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-3(4H)-quinazolinyl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-82-0P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-83-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(4,4-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254742-84-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254742-85-3P, Acetamide, N-[2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- 254742-86-4P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester 254742-87-5P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(propylamino)carbonyl]propyl]- 254742-88-6P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]propyl]- 254742-89-7P

, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-91-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-2'-(trifluoromethyl)- 254742-92-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)- 254742-93-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-methylpropoxy)methyl]- 254742-94-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(ethylsulfonyl)amino]- 254742-95-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2,2,2-trifluoroethoxy)methyl]- 254742-96-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]- 254742-97-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-98-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-99-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3,3,3-trifluoropropyl)- 254743-00-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3-fluoropropyl)- 254743-01-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(1,1-difluoroethyl)-N-(4,5-dimethyl-3-isoxazolyl)- 254743-03-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2,2-trifluoroethyl)- 254743-05-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methylpropoxy)- 254743-06-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methoxyethoxy)- 254743-08-3P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-10-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methoxymethylamino)methyl]- 254743-12-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(2,2-difluoroethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-15-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-fluoroethyl)- 254743-16-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-hydroxyethyl)- 254743-17-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3-methylbutyl)- 254743-18-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methylpropyl)- 254743-19-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(3,3-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)- 254743-20-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)- 254743-22-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-24-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254743-25-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-26-5P, 1H-Imidazole-5-carboxamide,

1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254743-27-6P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-28-7P 254743-29-8P 254743-30-1P 254743-31-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl- 254743-32-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)- 254743-33-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)- 254743-34-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-35-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-36-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-37-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-38-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-39-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-40-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-41-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-42-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-43-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-44-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-45-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-46-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-47-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-48-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-49-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-50-5P 254743-51-6P 254743-53-8P 254743-56-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-57-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-58-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- 254743-59-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-61-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-

254743-62-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(tetrahydro-2-furanyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-63-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)- 254743-64-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)- 254743-65-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(tetrahydro-2-furanyl)- 254743-66-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-67-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-68-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- 254743-69-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-70-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-71-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(tetrahydro-2-furanyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-72-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-2'-(3,3,3-trifluoropropyl)- 254743-73-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-2'-(3,3,3-trifluoropropyl)- 254743-74-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- 254743-75-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- 254743-76-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-77-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-propyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-78-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254743-79-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-80-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-81-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-82-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(2,2-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl- 254743-83-4P 254743-84-5P 254743-85-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[4-oxo-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254743-86-7P 254743-87-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[4-oxo-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-2'-propyl- 254743-88-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[4-oxo-2-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254743-89-0P

254743-90-3P 254743-91-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[4-oxo-2-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-2'-propyl- 254743-92-5P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-93-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-94-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-95-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-96-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1,1,3,3,3-pentafluoropropyl)- 254743-97-0P 254743-98-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-99-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-00-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-01-9P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-02-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-03-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-04-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-05-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-06-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-07-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-08-6P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-09-7P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-10-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-11-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-12-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-13-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 56-12-2, 4-Aminobutyric acid, reactions 75-03-6, Iodoethane 78-09-1, Tetraethyl orthocarbonate 79-03-8, Propionyl chloride 79-44-7, Dimethylcarbamyl chloride 95-89-6, 2-Chloro-3,6-dimethylpyrazine

109-81-9, N-Methylethylenediamine 124-40-3, Dimethylamine, reactions 127-08-2, Potassium acetate 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 589-15-1, 4-Bromobenzyl bromide 627-03-2, Ethoxyacetic acid 638-29-9, Valeryl chloride 676-58-4, Methylmagnesium chloride 680-15-9, Acetic acid, difluoro(fluorosulfonyl)-, methyl ester 767-00-0, 4-Cyanophenol 865-33-8, Potassium methoxide 873-75-6, 4-Bromobenzyl alcohol 1117-97-1, N-Methoxy-N-methylamine 1122-91-4, 4-Bromobenzaldehyde 1450-75-5, Ethanone, 1-(5-bromo-2-hydroxyphenyl)- 1530-32-1, Ethyltriphenylphosphonium bromide 1609-86-5, tert-Butyl isocyanate 2835-98-5, Phenol, 2-amino-5-methyl- 2905-25-1, 2-Bromobenzenesulfonyl chloride 3959-07-7, 4-Bromobenzylamine 4858-85-9, 2,3-Dichloropyrazine 5326-34-1, 4-Bromo-3-nitrotoluene 6228-47-3, Propyltriphenylphosphonium bromide 6482-24-2, 1-Bromo-2-methoxyethane 13734-41-3, L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- 14508-49-7, 2-Chloropyrazine 14678-02-5, 5-Amino-3-methylisoxazole 22059-22-9, Acetamide oxime 22884-29-3, Isobutyltriphenylphosphonium bromide 28466-21-9, 4-Amino-1,3,5-trimethylpyrazole 29006-02-8, Butanoic acid, 4-methoxy- 33670-32-5, Methoxymethyltriphenylphosphonium bromide 34328-47-7, Benzaldehyde, 4-bromo-3-(trifluoromethyl)- 34841-06-0, 3-Bromo-4-methoxybenzaldehyde 40155-28-0, 2-Chloro-3-methoxypyrazine 41963-20-6, 4-Bromo-3-methylbenzonitrile 53553-14-3, Methyl 2-chloro-3-nitrobenzoate 53596-60-4, Benzoic acid, 4-hydroxy-3-(2-propenyl)-, methyl ester 60421-23-0, Cyclopentanecarboxylic acid, 1-amino-, methyl ester, hydrochloride 74410-26-7, Butanamide, 2-amino-N,3-dimethyl-, monohydrochloride, (2S)- 76513-69-4, 2-(Trimethylsilyl)ethoxymethyl chloride 78775-11-8, Benzaldehyde, 4-bromo-3-methyl- 87199-17-5, 4-Formylphenylboronic acid 89464-87-9, 2-Amino-3-methoxy-5-methylpyrazine 98946-18-0, tert-Butyl 2,2,2-trichloroacetimidate 109072-25-5, 4(1H)-Quinolinone, 2-ethyl- 120077-69-2, Benzaldehyde, 4-bromo-3-chloro- 124750-49-8, 1H-Imidazole-4-carboxaldehyde, 5-chloro-2-propyl- 125110-82-9, 4,4-Difluoropentanoic acid 133059-43-5, Benzaldehyde, 4-bromo-3-fluoro- 133240-06-9, 1H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl- 138402-05-8, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl- 148547-19-7, Methyl 4-bromo-3-methylbenzoate 150691-04-6, Boronic acid, [2-[[(1,1-dimethylethyl)amino]sulfonyl]phenyl]- 151257-01-1, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-, monohydrochloride 153039-15-7, Butanoic acid, 4-amino-2,2-dimethyl-, hydrochloride 160313-50-8, Benzonitrile, 4-bromo-3-(1,3-dioxolan-2-yl)- 162647-41-8, 4-Pyridinol, 3-methoxy-2,6-dimethyl- 167985-34-4, 1H-Imidazole-4-carboxylic acid, 5-ethyl-2-propyl-, ethyl ester 176961-13-0, Boronic acid, [2-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]- 195436-86-3, Benzenesulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 254746-77-5, Boronic acid, [2-[[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]- 254746-78-6, Butanoic acid, 4-amino-2,2-dimethyl-, ethyl ester, hydrochloride 254746-79-7, Boronic acid, [2-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]phenyl]- 254746-80-0, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-N-[(2-methoxyethoxy)methyl]- 254746-81-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 14847-51-9P, Phenol, 2-bromo-5-methyl- 79047-47-5P, 1H-Imidazole-4-methanol, 5-chloro-2-propyl- 89003-95-2P, Benzonitrile, 4-bromo-3-formyl- 123652-98-2P, Benzene, 2-bromo-4-(dimethoxymethyl)-1-methoxy- 142031-67-2P, Benzoic acid, 4-bromo-3-(bromomethyl)-, methyl ester 160313-48-4P, Benzenemethanol, 4-bromo-3-(1,3-dioxolan-2-yl)- 176961-30-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]- 189762-06-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-

[(2-methoxyethoxy)methyl]- 189762-08-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl- 190197-86-5P, Benzonitrile, 4-bromo-3-(bromomethyl)- 254744-14-4P, Benzonitrile, 3-[(acetyloxy)methyl]-4-bromo- 254744-15-5P, Benzaldehyde, 4-bromo-3-(hydroxymethyl)- 254744-16-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-17-7P, Benzonitrile, 4-bromo-3-(methoxymethyl)- 254744-18-8P, Benzaldehyde, 4-bromo-3-(methoxymethyl)- 254744-19-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-20-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-21-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-22-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-23-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-24-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-25-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-26-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-methyl- 254744-27-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-4'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-28-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-29-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-30-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-N-[(2-methoxyethoxy)methyl]- 254744-31-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-32-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-methyl-4'-[[(methylsulfonyl)oxy]methyl]- 254744-33-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-34-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-methyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-35-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-36-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-37-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(methoxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-38-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-39-3P 254744-40-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-41-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-N-[(2-methoxyethoxy)methyl]- 254744-42-8P 254744-43-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-44-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-[(methylamino)methyl]- 254744-45-1P, Carbamic acid, [[4-cyano-2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-46-2P, Carbamic acid,

[[2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-4-formyl[1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-47-3P, Carbamic acid, [[4-(bromomethyl)-2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-48-4P 254744-49-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl]- 254744-50-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-4'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-51-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl]- 254744-52-0P 254744-53-1P, Benzaldehyde, 4-bromo-3-(1,3-dioxolan-2-yl)- 254744-54-2P, 1,3-Dioxolane, 2-[2-bromo-5-(bromomethyl)phenyl]- 254744-55-3P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(1,3-dioxolan-2-yl)phenyl]methyl]-2-butyl- 254744-56-4P 254744-58-6P 254744-60-0P 254744-63-3P 254744-65-5P 254744-68-8P 254744-70-2P 254744-73-5P, 1,2,4-Oxadiazole-5-methanamine, 3-methyl-α-(1-methylethyl)-, (αS)- 254744-78-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]amino]methyl]- 254744-81-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-84-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]- 254744-86-0P, Cyclopentanecarboxylic acid, 1-[(3-methoxy-1-oxopropyl)amino]-, methyl ester 254744-87-1P, Cyclopentanecarboxylic acid, 1-[(3-methoxy-1-oxopropyl)amino]- 254744-90-6P, Cyclopentanecarboxamide, 1-[(3-methoxy-1-oxopropyl)amino]- 254744-91-7P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(2-methoxyethyl)- 254744-95-1P, Cyclopentanecarboxylic acid, 1-[(ethoxyacetyl)amino]-, methyl ester 254744-98-4P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(ethoxymethyl)- 254745-00-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl]-4'-[(methylsulfonyl)oxy]- 254745-03-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-formyl-N-[(2-methoxyethoxy)methyl]- 254745-06-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254745-08-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254745-12-5P, Benzenesulfonamide, 2-bromo-N-(3-methyl-5-isoxazolyl)- 254745-14-7P, Benzenesulfonamide, 2-bromo-N-(3-methyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-19-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-formyl-N-(3-methyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-23-8P, Butanamide, N,3-dimethyl-2-[[[2'-[[(3-methyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, (2S)- 254745-28-3P, Pentanamide, N-[[2'-[[(3-methyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254745-31-8P, Benzonitrile, 4-bromo-3-(1-propenyl)- 254745-36-3P, Benzonitrile, 4-bromo-3-propyl- 254745-39-6P, Benzaldehyde, 4-bromo-3-propyl- 254745-42-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-propyl- 254745-43-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-propyl- 254745-45-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-4'-[[(methylsulfonyl)oxy]methyl]-2'-propyl- 254745-46-5P 254745-48-7P, Benzoic acid, 2-[[(4-bromophenyl)methyl]amino]-3-nitro-, methyl ester 254745-49-8P, Benzoic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-

[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-nitro-, methyl ester 254745-50-1P, Benzoic acid, 3-amino-2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester 254745-51-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254745-52-3P, Benzenemethanamine, 4-bromo-3-(1,3-dioxolan-2-yl)- 254745-53-4P, Benzoic acid, 2-[[[4-bromo-3-(1,3-dioxolan-2-yl)phenyl]methyl]amino]-3-nitro-, methyl ester 254745-54-5P, Benzoic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-formyl[1,1'-biphenyl]-4-yl]methyl]amino]-3-nitro-, methyl ester 254745-55-6P, Benzoic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-nitro-, methyl ester 254745-57-8P, Benzoic acid, 3-amino-2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester 254745-58-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254745-60-3P, Quinoline, 4-[(4-bromophenyl)methoxy]-2-ethyl- 254745-61-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254745-62-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254745-64-7P, [1,1'-Biphenyl]-2-sulfonic acid, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254745-66-9P, Ethanone, 1-(5-chloro-2-propyl-1H-imidazol-4-yl)- 254745-68-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-70-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(4-chloro-5-formyl-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-72-7P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254745-73-8P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254745-76-1P, 1H-Imidazole-5-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl-, ethyl ester 254745-77-2P, 1H-Imidazole-5-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254745-78-3P 254745-79-4P 254745-80-7P 254745-81-8P 254745-82-9P, Benzenesulfonamide, 2-bromo-N-(3-methoxy-5-methylpyrazinyl)- 254745-83-0P, Benzenesulfonamide, 2-bromo-N-(3-methoxy-5-methylpyrazinyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-84-1P 254745-85-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-formyl-N-(3-methoxy-5-methylpyrazinyl)- 254745-86-3P, Benzenesulfonamide, 2-bromo-N-[(2-methoxyethoxy)methyl]-N-(3-methyl-5-isoxazolyl)- 254745-87-4P, Boronic acid, [2-[[[(2-methoxyethoxy)methyl](3-methyl-5-isoxazolyl)amino]sulfonyl]phenyl]- 254745-88-5P 254745-89-6P 254745-90-9P 254745-91-0P, Benzene, 4-(dimethoxymethyl)-1-methoxy-2-(3,3,3-trifluoropropyl)- 254745-92-1P, Benzaldehyde, 4-methoxy-3-(3,3,3-trifluoropropyl)- 254745-93-2P, Benzaldehyde, 4-hydroxy-3-(3,3,3-trifluoropropyl)- 254745-94-3P, Methanesulfonic acid, trifluoro-, 4-formyl-2-(3,3,3-trifluoropropyl)phenyl ester 254745-95-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-96-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-97-6P

254745-98-7P, Benzoic acid, 3-(2-propenyl)-4-[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254745-99-8P, Benzoic acid, 3-(3-hydroxypropyl)-4-[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254746-00-4P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(3-hydroxypropyl)-, methyl ester 254746-01-5P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(3-fluoropropyl)-, methyl ester 254746-03-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-04-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-06-0P 254746-07-1P, Methanesulfonic acid, trifluoro-, 2-acetyl-4-bromophenyl ester 254746-08-2P, Methanesulfonic acid, trifluoro-, 4-bromo-2-(1,1-difluoroethyl)phenyl ester 254746-09-3P, Methanesulfonic acid, trifluoro-, 2-(1,1-difluoroethyl)-4-formylphenyl ester 254746-10-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-11-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-12-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-13-9P 254746-14-0P, Benzoic acid, 4-bromo-3-(2,2,2-trifluoroethyl)-, methyl ester 254746-15-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2,2,2-trifluoroethyl)-, methyl ester 254746-16-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-(2,2,2-trifluoroethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-18-4P 254746-19-5P, Benzene, 1-bromo-4-methyl-2-(2-methylpropoxy)- 254746-20-8P, Benzene, 1-bromo-4-(bromomethyl)-2-(2-methylpropoxy)- 254746-21-9P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(2-methylpropoxy)phenyl]methyl]-2-butyl- 254746-22-0P 254746-23-1P, Benzene, 1-bromo-2-(2-methoxyethoxy)-4-methyl- 254746-24-2P, Benzene, 1-bromo-4-(bromomethyl)-2-(2-methoxyethoxy)- 254746-25-3P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(2-methoxyethoxy)phenyl]methyl]-2-butyl- 254746-26-4P 254746-27-5P, Benzonitrile, 4-bromo-3-(1-butenyl)- 254746-28-6P, Benzonitrile, 4-bromo-3-butyl- 254746-29-7P, Benzaldehyde, 4-bromo-3-butyl- 254746-30-0P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-31-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-32-2P 254746-33-3P, Boronic acid, [2-[[(3-methyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]phenyl]- 254746-34-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-formyl-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-35-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(hydroxymethyl)-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-36-6P 254746-37-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-[(methoxymethylamino)methyl]- 254746-38-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-[(methoxymethylamino)methyl]- 254746-39-9P 254746-40-2P, Benzoic acid, 4-bromo-3-(hydroxymethyl)-, methyl ester 254746-41-3P, Benzoic acid, 3-[(acetyloxy)methyl]-4-bromo-, methyl ester 254746-42-4P, Benzoic acid, 4-bromo-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, methyl ester 254746-43-5P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]meth

yl]amino]sulfonyl]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, methyl ester 254746-44-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-45-7P 254746-46-8P 254746-47-9P 254746-48-0P, Benzoic acid, 3-(2-hydroxyethyl)-4-[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254746-49-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2-hydroxyethyl)-, methyl ester 254746-50-4P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2-fluoroethyl)-, methyl ester 254746-51-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-fluoroethyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-52-6P 254746-53-7P
, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester 254746-54-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-55-9P, Benzonitrile, 4-bromo-3-(3-methyl-1-butenyl)- 254746-56-0P, Benzonitrile, 4-bromo-3-(3-methylbutyl)- 254746-57-1P, Benzaldehyde, 4-bromo-3-(3-methylbutyl)- 254746-58-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(3-methylbutyl)- 254746-59-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(3-methylbutyl)- 254746-60-6P, Benzonitrile, 4-[(2-methyl-2-propenyl)oxy]- 254746-61-7P, Benzonitrile, 4-hydroxy-3-(2-methyl-2-propenyl)- 254746-62-8P, Benzonitrile, 4-hydroxy-3-(2-methylpropyl)- 254746-63-9P, Benzaldehyde, 4-hydroxy-3-(2-methylpropyl)- 254746-64-0P, Methanesulfonic acid, trifluoro-, 4-formyl-2-(2-methylpropyl)phenyl ester 254746-65-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-66-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-67-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-68-4P 254746-69-5P, Cyclopentanecarboxylic acid, 1-[(3,3-difluoro-1-oxobutyl)amino]-, methyl ester 254746-70-8P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(3,3-difluorobutyl)- 254746-71-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-72-0P, Benzoic acid, 4-bromo-3-[(1,1-dimethylethoxy)methyl]-, methyl ester 254746-73-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-, methyl ester 254746-74-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-75-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-76-4P 254746-82-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 50-78-2, Aspirin 52-01-7, Spironolactone 10238-21-8, Glyburide **51384-51-1**, **Metoprolol** 55142-85-3, Ticlopidine **72956-09-3**, **Carvedilol** 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin **107724-20-9**, **Eplerenone** 113665-84-2, Clopidogrel 134523-00-5, Atorvastatin 147098-20-2, Zd-4522 147526-32-7, NK 104 150322-43-3, Cs-747
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT **51384-51-1, Metoprolol 72956-09-3, Carvedilol 107724-20-9, Eplerenone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 51384-51-1 HCAPLUS
CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 72956-09-3 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:107159 HCAPLUS
DN 136:172753
ED Entered STN: 10 Feb 2002
TI Epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure
IN **Alexander, John C.; Schuh, Joseph R.**
PA **Pharmacia Corporation, USA**
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K045-06
ICS A61K031-58; A61P009-00; A61K031-58; A61K031-135; A61K045-06; A61K031-58
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002009760	A2	20020207	WO 2001-US23670	20010727 <--
WO 2002009760	A3	20030123		
WO 2002009760	C2	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2415789	AA	20020207	CA 2001-2415789	20010727 <--
US 2002123485	A1	20020905	US 2001-917403	20010727 <--
EP 1303306	A2	20030423	EP 2001-957290	20010727 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004511435	T2	20040415	JP 2002-515312	20010727	<--
US 2004235809	A1	20041125	US 2004-343166	20040607	<--
PRAI US 2000-221365P	P	20000727	<--		
WO 2001-US23670	W	20010727	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 2002009760	ICM	A61K045-06	
	ICS	A61K031-58; A61P009-00; A61K031-58; A61K031-135; A61K045-06; A61K031-58	
US 2002123485	ECLA	A61K031/58; A61K045/06	<--
JP 2004511435	FTERM	4C084/AA02; 4C084/AA03; 4C084/AA20; 4C084/BA36; 4C084/BA44; 4C084/CA59; 4C084/MA02; 4C084/NA05; 4C084/NA14; 4C084/ZA362; 4C084/ZA422; 4C084/ZC022; 4C086/AA01; 4C086/AA02; 4C086/BC12; 4C086/DA12; 4C086/DA13; 4C086/MA02; 4C086/MA04; 4C086/NA05; 4C086/NA14; 4C086/ZA36; 4C086/ZA42; 4C086/ZC02; 4C091/AA02; 4C091/BB05; 4C091/CC01; 4C091/DD01; 4C091/EE07; 4C091/FF01; 4C091/GG01; 4C091/GG02; 4C091/GG16; 4C091/HH01; 4C091/JJ03; 4C091/KK01; 4C091/LL01; 4C091/MM03; 4C091/NN01; 4C091/PA01; 4C091/PA03; 4C091/PA09; 4C091/PB01; 4C091/PB03; 4C091/QQ07; 4C091/QQ15; 4C091/QQ18; 4C204/BB01; 4C204/CB25; 4C204/DB01; 4C204/EB01; 4C204/FB01; 4C204/GB25; 4C206/AA01; 4C206/AA02; 4C206/FA14; 4C206/FA19; 4C206/FA21; 4C206/GA01; 4C206/GA31; 4C206/JA11; 4C206/MA02; 4C206/MA04; 4C206/MA21; 4C206/NA05; 4C206/NA14; 4C206/ZA36; 4C206/ZA42; 4C206/ZC02	<--
US 2004235809	ECLA	A61K031/58+M	<--

AB A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a **beta-adrenergic antagonist** is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred **beta-adrenergic antagonists** are those compds. having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9α, 11α-substituted epoxy moiety. A preferred combination therapy includes the **beta-adrenergic antagonist metoprolol** succinate and the aldosterone receptor antagonist **epoxymexrenone.** Crystal forms of **eplerenone** were prepared as well as the Me Et ketone solvate.

ST epoxy steroid aldosterone antagonist **beta adrenergic antagonist**; congestive heart failure treatment compn

IT Cardiovascular agents
Crystal morphology
Crystallization
Human
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT Heart, disease
(failure; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT **Adrenoceptor antagonists**
(β -; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT 170684-14-7, UK 1745
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(UK 1745; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT 52-39-1, Aldosterone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT 395665-44-8P 395665-46-0P
RL: BYP (Byproduct); PREP (Preparation)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT **344449-96-3**
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT **107724-20-9, Eplerenone**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT 52-01-7, Spironolactone **525-66-6, Propranolol 3930-20-9, Sotalol 6452-71-7, Oxprenolol** 7413-36-7, Nifenalol **13523-86-9, Pindolol** 13655-52-2, Alprenolol **22664-55-7, Metipranolol** 23694-81-7, Mepindolol **26839-75-8, Timolol 29122-68-7, Atenolol** 34915-68-9, Bunitrolol **36894-69-6, Labetalol 37517-30-9, Acebutolol 38363-40-5, Penbutolol** 39552-01-7, Befunolol 39563-28-5, Cloranolol **42200-33-9, Nadolol 47141-42-4, Levobunolol 51384-51-1, Metoprolol 51781-06-7, Carteolol 56980-93-9, Celiprolol** 57460-41-0, Talinolol 57775-29-8, Carazolol 58409-59-9, Bucumolol 58930-32-8, Butofilolol 59170-23-9, Bevantolol 60607-68-3, Indenolol **62658-63-3, Bopindolol 63659-18-7, Betaxolol 66722-44-9, Bisoprolol 66848-46-2**, Viskenit 68377-92-4, Arotinolol **71119-11-4, Bucindolol 72956-09-3, Carvedilol** 77164-20-6, Levomoprolol **81147-92-4, Esmolol** 81447-80-5, Diprafenone 81486-22-8, Nipradilol 81801-12-9, Xamoterol 83688-84-0, Tertatolol 85136-71-6, Tilisolol 85320-68-9, Amosulalol 93379-54-5, S-**Atenolol 98418-47-4**, Toprol xl 102203-23-6, Acc 9369 114856-47-2, TZC-5665 115609-61-5, L-653328 **118457-14-0, Nebivolol** 125279-79-0, Ersentilide 132017-03-9, SR 58894A 133242-30-5, Landiolol 153192-22-4, YM-430 153601-03-7, Capsinolol 165337-66-6, LM-2616 174689-39-5, SR-59230A

188564-74-1, Fr-172516 207922-70-1 264134-39-6, SB-226552
395665-48-2 395665-50-6 395665-52-8 395665-54-0
395665-56-2 395665-58-4 395665-60-8 395665-62-0 395665-64-2
395665-66-4 395665-68-6 396654-09-4 396712-03-1, AMO 140
396712-06-4, ISV 208 396712-07-5, PharmaProjects 5279
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

IT **344449-96-3**
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)

RN 344449-96-3 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)-, compd. with 2-butanone (9CI) (CA INDEX NAME)

CM 1

CRN 107724-20-9
CMF C24 H30 O6

Absolute stereochemistry.



CM 2

CRN 78-93-3
CMF C4 H8 O



IT **107724-20-9, Eplerenone**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for

treatment of congestive heart failure)
RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **525-66-6, Propranolol 3930-20-9, Sotalol 6452-71-7, Oxprenolol 13523-86-9, Pindolol 22664-55-7, Metipranolol 26839-75-8, Timolol 29122-68-7, Atenolol 36894-69-6, Labetalol 37517-30-9, Acebutolol 38363-40-5, Penbutolol 42200-33-9, Nadolol 47141-42-4, Levobunolol 51384-51-1, Metoprolol 51781-06-7, Carteolol 56980-93-9, Celiprolol 62658-63-3, Bopindolol 63659-18-7, Betaxolol 66722-44-9, Bisoprolol 66848-46-2**, Viskenit **71119-11-4, Bucindolol 72956-09-3, Carvedilol 81147-92-4, Esmolol 98418-47-4**, Toprol xl **118457-14-0, Nebivolol 395665-48-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxy-steroidal aldosterone antagonist and **beta-adrenergic antagonist** combination therapy for treatment of congestive heart failure)
RN 525-66-6 HCAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 3930-20-9 HCAPLUS
CN Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 6452-71-7 HCAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 13523-86-9 HCAPLUS
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 22664-55-7 HCAPLUS
CN Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate (9CI) (CA INDEX NAME)



RN 26839-75-8 HCAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 36894-69-6 HCAPLUS
CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 37517-30-9 HCAPLUS
CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 38363-40-5 HCAPLUS
CN 2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42200-33-9 HCAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 47141-42-4 HCAPLUS
CN 1(2H)-Naphthalenone, 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51384-51-1 HCAPLUS
CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 51781-06-7 HCAPLUS

CN 2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 56980-93-9 HCAPLUS
CN Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 62658-63-3 HCAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[(2-methyl-1H-indol-4-yl)oxy]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 63659-18-7 HCAPLUS
CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 66722-44-9 HCAPLUS
CN 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 66848-46-2 HCAPLUS
CN D-Glucitol, 1,4:3,6-dianhydro-, dinitrate, mixt. with 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol (9CI) (CA INDEX NAME)

CM 1

CRN 13523-86-9
CMF C14 H20 N2 O2



CM 2

CRN 87-33-2
CMF C6 H8 N2 O8

Absolute stereochemistry.



RN 71119-11-4 HCAPLUS
CN Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 72956-09-3 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 81147-92-4 HCAPLUS
CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 98418-47-4 HCAPLUS
CN Butanedioic acid, compd. with 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 51384-51-1
CMF C15 H25 N O3



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 118457-14-0 HCAPLUS
CN 2H-1-Benzopyran-2-methanol, α,α'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, (αR,α'R,2R,2'S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 395665-48-2 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:259979 HCAPLUS
DN 132:288794
ED Entered STN: 21 Apr 2000

TI Sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance

IN Anker, Stefan Dietmar; Coats, Andrew Justin Stewart
PA Imperial College Innovations Limited, UK

SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021509	A2	20000420	WO 1999-GB3302	19991015 <--
	WO 2000021509	A3	20001109		
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1121111	A2	20010808	EP 1999-947762	19991015 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002527378	T2	20020827	JP 2000-575485	19991015 <--
PRAI	GB 1998-22458	A	19981015 <--		
	GB 1998-22459	A	19981015 <--		
	GB 1999-17181	A	19990723 <--		
	WO 1999-GB3302	W	19991015 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000021509	ICM	A61K031-00

AB A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia. The sympathetic nervous system activity-reducing agents may also be used to treat weight loss due to aging and to enhance exercise performance.

ST sympathetic agent disease related wt loss; age related wt loss sympathetic agent; exercise performance cardiac cachexia sympathetic agent

IT Anabolic agents
(anabolic growth factors; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Angiotensin receptor antagonists
(angiotensin II; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Endothelin receptors
Imidazoline receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Reflex
(cardiovascular; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Lung, disease
(chronic obstructive; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Infection
(chronic; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Muscle
(elec. stimulation of; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxysuccinyl; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Heart, disease
Kidney, disease
(failure, chronic; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Nervous system agents
(ganglionic blocking agents; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Body weight
(loss; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT AIDS (disease)
Aging, animal
Cachexia
Cirrhosis
Disease, animal
Emphysema
Exercise
Heart, disease
Hypertension
Malnutrition
Neoplasm
Nervous system agents
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Opioids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Nervous system
(sympathetic; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)
IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α, antagonists; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT Adrenoceptor antagonists
(α-; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT **Adrenoceptor antagonists**
(β -; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 180384-56-9, Ro 61-1790
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ro 61-1790; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 188307-16-6, T 0201
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T 0201; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 52-39-1, Aldosterone
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(and aldosterone antagonists; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 9002-17-9, Xanthine oxidase 9004-08-4, Cathepsin 9015-82-1, Angiotensin-converting enzyme 9047-22-7, Cathepsin B 97501-92-3, Chymase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 9002-72-6, Growth hormone 67763-96-6, IGF-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 51-34-3, Scopolamine 52-01-7, Spironolactone 52-01-7D, Spironolactone, 15,16-methylene derivs. 57-27-2, Morphine, biological studies 60-26-4, Hexamethonium 60-30-0, Azamethonium 60-40-2, Mecamylamine 68-91-7 71-91-0, Tetraethylammonium bromide 100-33-4, Pentamidine 119-44-8, Xanthopterin 125-28-0, Dihydrocodeine 144-44-5, Pentolinium 315-30-0, Allopurinol 382-82-1 492-11-5, Leukopterin 497-23-4, 2(5H)-Furanone **525-66-6**, **Propranolol** 546-48-5, Synapleg 555-30-6, α-Methyldopa 561-27-3, Diamorphine 968-93-4, Testolactone 971-60-8, Benzohexonium 1218-98-0, 7,8-Dihydroneopterin 2009-64-5, Neopterin 2365-25-5, Pentamethonium 2465-59-0, Oxypurinol 3613-69-2, Cypenam **3930-20-9**, **Sotalol** 4138-96-9 4205-90-7, Clonidine 4844-10-4, Hexafluorenium 5472-41-3, 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidine **6452-71-7**, **Oxprenolol** 7187-66-8, Trimetaphan 9087-70-1, Aprotinin 11096-26-7, Erythropoietin **13523-86-9**, **Pindolol** 13655-52-2, Alprenolol 17528-72-2 19216-56-9, Prazosin 22150-76-1, Biopterin **22664-55-7**,

Metipranolol 26839-75-8, Timolol
29122-68-7, Atenolol 36894-69-6
37517-30-9, Acebutolol 38363-40-5,
Penbutolol 42200-33-9, Nadolol
47141-42-4, Levobunolol 51384-51-1,
Metoprolol 51781-06-7, Carteolol 52485-79-7,
Buprenorphine 54187-04-1, Rilmenidine **56980-93-9,**
Celiprolol 63590-64-7, Terazosin **63659-18-7,**
Betaxolol 66376-36-1, Alendronate **66722-44-9**
67392-87-4, Dihydrospirorenone **71119-11-4, Bucindolol**
72956-09-3, Carvedilol 74191-85-8, Doxazosin
74220-07-8, Spirorenone 75438-57-2, Moxonidine 76676-33-0, RU26752
76684-89-4, E 64c **81147-92-4, Esmolol** 86102-31-0,
Tissue inhibitor of matrix metalloproteinase 87952-98-5, Mespirenone
91448-99-6, Cystatin C 93519-21-2 95847-70-4, Ipsapirone
107544-29-6, Stefin A **107724-20-9, Eplerenone**
118457-14-0, Nebivolol 134448-10-5, CA-074
136553-74-7, WS 7338B 136553-81-6, BQ123 144602-02-8, IRL 1038
145380-08-1, RU40555 151039-33-7, PD 142893 156161-89-6, BQ-788
157659-79-5, SB 209670 162117-90-0, S 0139 162412-70-6, PD 156707
171714-84-4, LU135252 173189-01-0, IRL 3461 173937-91-2, ABT-627
204326-22-7, PD 164333 223756-43-2, A-216546 264276-89-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 75847-73-3, Enalapril 114798-26-4, Losartan
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT 51-41-2, Noradrenaline 51-43-4, Epinephrine 11128-99-7, Angiotensin II
123626-67-5, Endothelin 1
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

IT **525-66-6, Propranolol 3930-20-9,**
Sotalol 6452-71-7, Oxprenolol
13523-86-9, Pindolol 22664-55-7,
Metipranolol 26839-75-8, Timolol
29122-68-7, Atenolol 36894-69-6
37517-30-9, Acebutolol 38363-40-5,
Penbutolol 42200-33-9, Nadolol
47141-42-4, Levobunolol 51384-51-1,
Metoprolol 51781-06-7, Carteolol
56980-93-9, Celiprolol 63659-18-7,
Betaxolol 66722-44-9 71119-11-4,
Bucindolol 72956-09-3, Carvedilol
81147-92-4, Esmolol 107724-20-9,
Eplerenone 118457-14-0, Nebivolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sympathetic nervous system activity-reducing agents for treatment of disease- or age-related weight loss and for enhancement of exercise performance)

RN 525-66-6 HCAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 3930-20-9 HCAPLUS
CN Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 6452-71-7 HCAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 13523-86-9 HCAPLUS
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 22664-55-7 HCAPLUS
CN Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate (9CI) (CA INDEX NAME)



RN 26839-75-8 HCAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 29122-68-7 HCAPLUS
CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 36894-69-6 HCAPLUS
CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 37517-30-9 HCAPLUS
CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 38363-40-5 HCAPLUS
CN 2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42200-33-9 HCAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 47141-42-4 HCAPLUS
CN 1(2H)-Naphthalenone, 5-[(2S)-3-[(1,1-dimethylethyl)amino]-2-
hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51384-51-1 HCAPLUS
CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 51781-06-7 HCAPLUS
CN 2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 56980-93-9 HCAPLUS
CN Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 63659-18-7 HCAPLUS
CN 2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 66722-44-9 HCAPLUS
CN 2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 71119-11-4 HCAPLUS
CN Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 72956-09-3 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 81147-92-4 HCAPLUS
CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 118457-14-0 HCAPLUS
CN 2H-1-Benzopyran-2-methanol, α,α'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, (αR,α'R,2R,2'S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> => d l78 all hitstr tot

L78 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:927079 HCAPLUS
DN 141:360723
ED Entered STN: 04 Nov 2004
TI Growth hormone receptor antagonist-COX-2 inhibitor combination with

antihypertension agents for use in treatment of patients with acromegaly
IN Fryklund, Linda; Harris, Philip
PA **Pharmacia & Upjohn Company, USA**
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K045-06
ICS A61K038-27; A61K031-585; A61P009-12
CC 1-12 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093913	A1	20041104	WO 2004-GB1771	20040426

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2003-9328 A 20030424
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004093913	ICM	A61K045-06
	ICS	A61K038-27; A61K031-585; A61P009-12
WO 2004093913	ECLA	A61K031/585+M; A61K038/27+M; A61K045/06

AB The invention provides a method for the treatment of hypertension in a patient characterized by using a growth hormone receptor antagonist in combination with an antihypertension agent.
ST hypertension treatment acromegaly growth hormone receptor antagonist; pegvisomant treatment hypertension acromegaly
IT Angiotensin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiotensin II, inhibitors, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT Diuretics
Vasodilators
(as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT Ion channel blockers
(calcium, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT Acromegaly
Antihypertensives
Drug delivery systems
Human
Hypertension
(growth hormone receptor antagonist-COX-2 inhibitor combination with

antihypertension agents for use in treatment of patients with acromegaly)
IT Growth hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT Polyoxyalkylenes, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human growth hormone conjugates; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT Drug delivery systems
(prodrugs; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT **Adrenoceptor antagonists**
(β -, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT 83150-76-9, Octreotide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conversion to pegvisomant; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT 9002-72-6D, Somatotropin, variants and pegylated forms 25322-68-3D, Polyethylene glycol, human growth hormone conjugates **107724-20-9**, **Eplerenone** 218620-50-9, Pegvisomant
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT 9015-94-5, Renin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypertension comprising low levels of; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
IT 9015-82-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, as anti-hypertensive agents; growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Coats, A; INTERNATIONAL JOURNAL OF CARDIOLOGY, CAPLUS 2001:495110 2001, V80(1), P1 MEDLINE
(2) Goffin, V; CURRENT OPINION IN INVESTIGATIONAL DRUGS 2002, V3(5), P752 HCAPLUS
(3) McMahon, E; CURRENT OPINION IN PHARMACOLOGY 2001, V1(2), P190 HCAPLUS
(4) Zillich, A; ANNALS OF PHARMACOTHERAPY 2002, V36(10), P1567 HCAPLUS
IT **107724-20-9**, **Eplerenone**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly)
RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:905610 HCAPLUS
DN 141:374739
ED Entered STN: 29 Oct 2004
TI Combination of an aldosterone receptor antagonist and an anti-obesity agent
IN Gulve, Eric Arthur; McMahon, Ellen Garwitz
PA **Pharmacia Corporation, USA**
SO U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-56
NCL 514171000
CC 1-11 (Pharmacology)
Section cross-reference(s): 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214804	A1	20041028	US 2004-814870	20040401
	WO 2004096132	A2	20041111	WO 2004-US12205	20040420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2003-465213P	P	20030425
	US 2004-814870	A	20040401

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004214804	ICM	A61K031-56
	NCL	514171000

AB A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a therapeutically-effective amount of an

anti-obesity agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred anti-obesity agents are those compds. having high potency and bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9α,11α-substituted epoxy moiety.

ST aldosterone receptor antagonist antiobesity agent cardiovascular disorders treatment

IT 5-HT antagonists
(5-HT2C; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ASBT (apical sodium-dependent bile acid transporter), inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Cholecystokinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCKA, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y1, antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Y5, antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Cytokines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adiponectin; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Angiotensin receptor antagonists
(angiotensin I; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Angiotensin receptor antagonists
(angiotensin II; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Endothelin receptors
Glucocorticoid receptors
Glucocorticoids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Antiarteriosclerotics
(antiatherosclerotics; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Heart, disease
(arrhythmia; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Liver, disease

(ascites and congestion; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Ion channel blockers
(calcium; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Brain, disease
(cerebrovascular; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 5-HT reuptake inhibitors
Anti-ischemic agents
Antiarrhythmics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antioxidants
Appetite depressants
Atherosclerosis
Blood vessel, disease
Cardiovascular agents
Cardiovascular system, disease
Combination chemotherapy
Diuretics
Drug interactions
Edema
Human
Hyperglycemia
Hypertension
Ischemia
Kidney, disease
Liver, disease
Obesity
Thrombosis
Vasodilators
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Cannabinoid receptors
Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Ciliary neurotrophic factor
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Spleen, disease
(congestion; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Artery, disease
(coronary; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and

combination with third agent)
IT Kidney, disease
(diabetic nephropathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Circulation
(disorder; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Baroreceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dysfunction; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Blood vessel, disease
(endothelium; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Kidney, disease
(failure, chronic; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Heart, disease
(failure; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Blood vessel, disease
Heart, disease
Kidney, disease
(fibrosis; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Kidney, disease
(glomerulosclerosis; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glp-1, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Heart, disease
(hypertrophic cardiomyopathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Heart, disease
(infarction; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Gastric emptying
(inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Blood vessel, disease
(injury; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Diabetes mellitus
(insulin-dependent; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)
IT Kidney, disease
(ischemia; combination of an aldosterone receptor antagonist and an

anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Heart, disease
(left ventricle, hypertrophy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Ascites
(liver; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Pituitary hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin receptor 4, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Disease, animal
(metabolic syndrome X; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(microalbuminuria; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Kidney, disease
(nephrosclerosis, malignant; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Nerve, disease
(neuropathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Diabetes mellitus
(non-insulin-dependent; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Nervous system agents
(noradrenaline reuptake inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Artery, disease
(proliferative arteriopathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proteinuria; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Eye, disease
(retinopathy; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Appetite
(satiety, increase of; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequestrants; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Brain, disease

(stroke; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Death
(sudden death, cardiac; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Kidney, disease
(thrombotic lesions; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Endothelium
(vascular, disease; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Adrenoceptor antagonists
(α-; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(αIIbβ3, antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β, agonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT **Adrenoceptor antagonists**
(β -; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(absorption inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 62571-86-2, Captopril 75847-73-3, Enalapril 76547-98-3, Lisinopril 82834-16-0, Perindopril 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88768-40-5, Cilazapril 98048-97-6, Fosinopril
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin converting enzyme inhibitor; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 9041-90-1, Angiotensin I 82785-45-3, Neuropeptide Y
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 657-24-9, Metformin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 138238-81-0, Endothelin converting enzyme 1 766549-20-6, Endothelin converting enzyme 2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with

third agent)

IT 52-01-7, Spironolactone 59-67-6, Niacin, biological studies 1406-18-4, Vitamin E 9002-72-6D, Somatotropin, fragments 23288-49-5, Probucol 89750-14-1, GLP-1 95716-76-0 95716-78-2 95716-94-2 95716-98-6 95716-99-7 95717-01-4 95717-02-5 96829-58-2, Orlistat 106650-56-0, Sibutramine **107724-20-9** 141732-76-5, Exendin 4 149820-74-6, Xemilofiban 163250-90-6, Orbofiban 168273-06-1, SR-141716 395665-58-4 416839-88-8, Axokine 430433-43-5, CP 644673 782479-58-7 782479-59-8 782482-03-5, HMR 1426 782482-04-6, GI 181771 782482-05-7, BVT 933
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 60-27-5, Creatinine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(decreased clearance; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 943-45-3, Fibric acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs.; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 9001-62-1, Lipase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gastrointestinal, inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperinsulinemia and resistance; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 9028-35-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, statins; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT 9015-82-1 9015-94-5, Renin, biological studies 9023-93-2, Acetyl CoA carboxylase 9041-46-7, 11β-Hydroxysteroid dehydrogenase 1 9045-77-6, Fatty acid synthase 54249-88-6, DPP-IV 300865-11-6, PTP-1B 329900-75-6, Cyclooxygenase-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

IT **107724-20-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of an aldosterone receptor antagonist and an anti-obesity agent for treatment of cardiovascular disorders and combination with third agent)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:802700 HCAPLUS
DN 141:289096
ED Entered STN: 01 Oct 2004
TI Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
IN Mcmahon, Ellen G.; Rudolph, Amy E.
PA **Pharmacia Corporation, USA**
SO PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-12 (Pharmacology)
Section cross-reference(s): 2, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004082636	A2	20040930	WO 2004-US8220	20040318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004192584	A1	20040930	US 2004-803317	20040318
PRAI US 2003-455738P	P	20030318		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004082636	ICM	A61K
WO 2004082636	ECLA	A61K031/56+M; A61K045/06
US 2004192584	ECLA	A61K031/56+M; A61K045/06

AB Combinations, compns., and therapeutic methods of treatment and/or prophylaxis of a hypertension, cardiovascular disease, renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathol. condition in a subject are described. Methods for prophylaxis or treatment of a pathol. condition comprise the administration of (i) a combination of one or more aldosterone receptor antagonists and one or more neutral endopeptidase

(NEP) inhibitors, (ii) a combination of one or more aldosterone receptor antagonists, one or more NEP inhibitors, and one or more ACE inhibitors, (iii) or a combination of one or more aldosterone receptor antagonists and one or more vasopeptidase inhibitors selected from a specific group of compds. described herein. The aldosterone receptor antagonist is administered in a daily dose ranging from about 0.1 to 2000 mg, the NEP inhibitor is administered in a daily dose ranging from about 0.1 to 1000 mg, and the ACE inhibitor is administered in a daily dose ranging from about 0.1 to 1000 mg. A kit is also described containing a first amount of an aldosterone receptor antagonist and a second amount of an inhibitor selected from the group consisting of (1) a vasopeptidase inhibitor, wherein the first amount of the aldosterone receptor antagonist exhibits a release profile, determined using a suitable release profile test, in which more than about 20% by weight of the aldosterone receptor antagonist is released within about 4 h after initiation of the test, (2) a vasopeptidase inhibitor other than omapatrilat, and (3) a neutral endopeptidase inhibitor. Clin. therapy protocols for combination therapy are outlined.

ST aldosterone receptor antagonist neutral endopeptidase vasopeptidase inhibitor therapy

IT Endothelin receptors
Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bile acid-sodium-cotransporter, inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Sequestering agents
(bile; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Ion channel blockers
(calcium; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Brain, disease
(cerebrovascular; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesteryl ester-transporting, inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Antioxidants
Blood vessel, disease
Cardiovascular system, disease
Combination chemotherapy
Diuretics
Edema
Human
Hypertension
Kidney, disease
Liver, disease
Vasodilators
(combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Baroreceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dysfunction; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Blood vessel, disease
(endothelium, dysfunction; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Drug delivery systems
(kits; combination therapy with aldosterone receptor antagonist and

neutral endopeptidase inhibitor)

IT Nerve, disease
(neuropathy; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Eye, disease
(retinopathy; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Adrenoceptor antagonists
(α-; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT Integrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(αIIbβ3, antagonists; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT **Adrenoceptor antagonists**
(β -; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(absorption inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9041-90-1, Angiotensin I 11128-99-7, Angiotensin II
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 59-67-6, Niacin, biological studies 1406-18-4, Vitamin E 23288-49-5, Probucol 36357-77-4, Phosphoramidon 62571-86-2, Captopril 75847-73-3, Enalapril 76547-98-3, Lisinopril 81110-73-8, Racecadotril 82586-55-8, Quinopril 82834-16-0, Perindopril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88768-40-5, Cilazapril 95716-76-0 95716-78-2 95716-94-2 95716-95-3 95716-96-4 95716-97-5 98048-97-6, Fosinopril **107724-20-9**, **Eplerenone** 112573-73-6, Ecadotril 123122-54-3, Candoxatrilat 123122-55-4, Candoxatril 129981-36-8, Sampatrilat 135038-57-2, Fasidotril 138238-81-0, Endothelin-converting enzyme 142695-08-7, M100240 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat 763102-14-3 763102-15-4 763102-16-5 763102-17-6 763102-18-7 763139-71-5, GW 660511
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9028-35-7, Hydroxymethylglutaryl-CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, statins; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9015-82-1, Vasopeptidase 9015-94-5, Renin, biological studies 82707-54-8, Neutral endopeptidase 329900-75-6, Cyclooxygenase-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(insulinopathy; combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

IT **107724-20-9**, **Eplerenone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with aldosterone receptor antagonist and neutral endopeptidase inhibitor)

RN 107724-20-9 HCAPLUS

CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:780354 HCAPLUS
DN 141:289052
ED Entered STN: 24 Sep 2004
TI Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for the treatment of cardiovascular and other conditions
IN McMahon, Ellen G.; Rudolph, Amy E.
PA **Pharmacia Corporation, USA**
SO U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-56
NCL 514171000
CC 1-8 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004186083	A1	20040923	US 2004-803818	20040318
WO 2004082637	A2	20040930	WO 2004-US8250	20040318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-455580P P 20030318
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004186083	ICM	A61K031-56
	NCL	514171000
US 2004186083	ECLA	A61K031/56+M; A61K045/06
WO 2004082637	ECLA	A61K031/56+M; A61K045/06

AB The invention describes combinations, compns., and therapeutic methods of treatment and/or prophylaxis of hypertension, cardiovascular disease,

renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathol. conditions in a subject, wherein the methods comprise the administration of a combination of one or more aldosterone receptor antagonists and one or more endothelin receptor antagonist and/or ECE inhibitors.

ST endothelin aldosterone receptor antagonist combination therapeutic; aldosterone receptor endothelin converting enzyme inhibitor combination therapeutic; cardiovascular cerebrovascular renal therapeutic endothelin aldosterone receptor antagonist combination; edema insulinopathy endothelin aldosterone receptor antagonist combination

IT Angiotensin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiotensin I antagonists; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Angiotensin receptor antagonists
(angiotensin II; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Antiarteriosclerotics
(antiatherosclerotics; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(apical sodium bile acid transport inhibitors; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Heart, disease
(arrhythmia; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Liver
(ascites; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Sequestering agents
(bile acid; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Ion channel blockers
(calcium; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Heart, disease
(cardiac lesions; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Brain, disease
(cerebrovascular; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, inhibitors; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Anti-ischemic agents
Antiarrhythmics
Anticoagulants

Antidiabetic agents
Antihypertensives
Antioxidants
Atherosclerosis
Blood vessel, disease
Cardiovascular agents
Cardiovascular system, disease
Cirrhosis
Combination chemotherapy
Cytotoxic agents
Diuretics
Drug delivery systems
Edema
Human
Hypertension
Ischemia
Kidney, disease
Liver, disease
Nervous system agents
Thrombosis
Vasodilators
(combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Endothelin receptors
Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Lung, disease
Respiratory tract, disease
(congestion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Artery
(coronary, fibrinoid necrosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Blood vessel
(damage; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Heart, disease
(decreased ejection fraction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Blood vessel, disease
(decreased vascular compliance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Kidney, disease
(diabetic nephropathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Blood pressure
(diastolic, diastolic dysfunction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Baroreceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dysfunction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Endothelium
(endothelial dysfunction and thickening; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxysteroids; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney, disease
(failure, chronic; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(failure; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(fibrosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Capillary vessel
(focal thrombosis of glomerular capillaries; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Necrosis
(global fibrinoid; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney, disease
(glomerulosclerosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney
(glomerulus, glomerular filtration; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Liver, disease
(hepatic congestion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(hypertrophic cardiomyopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Artery, disease
(impaired arterial compliance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(infarction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme

inhibitor for treatment of cardiovascular and other conditions)
IT Diabetes mellitus
(insulin-dependent; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Disease, animal
(insulinopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney, disease
(ischemia; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(left ventricle, hypertrophy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Ascites
(liver; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney
(mesangium, reticulated mesangial matrix expansion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Disease, animal
(metabolic syndrome X; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(microalbuminuria; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(myocardial necrotic lesions; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney, disease
(nephrosclerosis, malignant; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Nerve, disease
(neuropathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Diabetes mellitus
(non-insulin-dependent; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Animal tissue
(peripheral tissue edema; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Disease, animal
(pre-diabetic; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Drug delivery systems
(prodrugs; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Artery, disease
(proliferative arteriopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proteinuria; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Kidney, disease
(reduced blood flow; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Artery
(renal, renal arteriopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Eye, disease
(retinopathy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Spleen
(splenic congestion; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Brain, disease
(stroke; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Heart, disease
(sudden cardiac death; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Blood pressure
(systolic, systolic dysfunction; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Liver
(toxicity, ascites; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Drug delivery systems
(unit doses; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Blood vessel, disease
(vascular fibrosis; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Blood vessel, disease
(vascular wall hypertrophy; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)
IT Adrenoceptor antagonists
(α-; combination of aldosterone receptor antagonist and

endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(αIIbβ3, antagonists; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT **Adrenoceptor antagonists**
(β -; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 174767-80-7, Sch 54470
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Sch 54470; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 245660-81-5, TMC 66
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TMC 66; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol absorption inhibitors; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 52-01-7, Spironolactone. 59-67-6, Niacin, biological studies 943-45-3D, Fibric acid, derivs. 1406-18-4, Vitamin E 23288-49-5, Probucol 36357-77-4, Phosphoramidon **107724-20-9**, **Eplerenone** 147536-97-8, Bosentan 154116-31-1, CGS 26303 162990-71-8, FR901533 167256-08-8, Enrasentan 169319-62-4, CGS-30440 171714-84-4, Darusentan 173937-91-2, Atrasentan 177036-94-1, Ambrisentan 180384-57-0, Tezosentan 182821-27-8, SLV-306 184036-34-8, Sitaxsentan 186366-61-0, CGS-26670 194542-56-8, SM-19712 208765-45-1, CGS 31447 **395665-48-2** 395665-50-6 395665-56-2 395665-58-4 395665-60-8 395665-62-0 395665-64-2 395665-66-4 395665-68-6 396068-70-5 761406-93-3 762262-08-8, KC 12615 762262-10-2, KC 90095-1AC
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 60-27-5, Creatinine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(decreased clearance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 9028-35-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, statins; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 9015-82-1, Angiotensin converting enzyme 9015-94-5, Renin, biological studies 138238-81-0, Endothelin converting enzyme 329900-75-6, Cyclooxygenase-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combination of aldosterone receptor antagonist and

endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT 50-99-7, D-Glucose, biological studies 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

IT **107724-20-9, Eplerenone 395665-48-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of aldosterone receptor antagonist and endothelin receptor antagonist and/or endothelin converting enzyme inhibitor for treatment of cardiovascular and other conditions)

RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395665-48-2 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L78 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:610248 HCAPLUS
DN 139:169328
ED Entered STN: 08 Aug 2003
TI Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
IN McMahon, Ellen G.; Rudolph, Amy E.
PA **Pharmacia Corporation, USA**
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063846	A2	20030807	WO 2003-US2723	20030130
	WO 2003063846	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003199483	A1	20031023	US 2003-354653	20030130
	EP 1469862	A2	20041027	EP 2003-710786	20030130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007336	A	20041207	BR 2003-7336	20030130
PRAI	US 2002-353801P	P	20020130		
	WO 2003-US2723	W	20030130		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003063846	ICM	A61K031-00

AB A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a amount of an α-adrenergic modulating agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred α-adrenergic modulating agents are those compds. having high potency and bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9,11-substituted epoxy moiety. A preferred combination therapy includes an α1-adrenergic antagonist or an α2-adrenergic agonist and the aldosterone receptor antagonist **epoxymexrenone.** Thus, a solution contains 0.5% dapiprazole and **eplerenone.**

ST aldosterone receptor antagonist adrenergic pathogenic
IT Antihypertensives
Ascites
Cardiovascular system, disease
Cirrhosis
Dissolution
Human
Hypertension
Inotropics
(aldosterone receptor antagonist and α-adrenergic modulators

combination therapy for prevention or treatment of pathogenic conditions)

IT Mineralocorticoid receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Drug delivery systems
(capsules; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxy-containing; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Heart, disease
Heart, disease
(failure; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Drug delivery systems
(injections; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Drug delivery systems
(solns.; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Drug delivery systems
(tablets; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Adrenoceptor antagonists
(α-; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Adrenoceptor antagonists
(α1-; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT Adrenoceptor antagonists
(α2-; aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

IT 50-60-2, Phentolamine 52-01-7, Spironolactone 59-96-1, Phenoxybenzamine 59-98-3, Tolazoline 146-48-5, Yohimbine 151-21-3, SDS, biological studies 4205-90-7, Clonidine 5051-62-7, Guanabenz 5053-06-5, Fenspiride 19216-56-9, Prazosin 26844-12-2, Indoramin 27848-84-6, Nicergoline 29110-47-2, Guanfacine 34661-75-1, Urapidil 35795-16-5, Trimazosin **36894-69-6**, **Labetalol** 54187-04-1, Rilmenidine 57149-07-2, Naftopidil 63590-64-7, Terazosin 66711-21-5, Apraclonidine 68377-92-4, Arotinolol 72822-12-9, Dapiprazole 74050-98-9, Ketanserin 74191-85-8, Doxazosin 75438-57-2, Moxonidine 77606-94-1, SUN 9221 80755-51-7, Bunazosin 81403-80-7, Alfuzosin 85320-68-9, Amosulalol 95716-76-0 95716-78-2 95716-94-2 95716-95-3 95716-96-4 95716-97-5 95716-98-6 95716-99-7 95717-02-5 103377-41-9, Monatepil 106133-20-4, Tamsulosin **107724-20-9**, **Eplerenone** 149882-25-7 150284-32-5, S 2150
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic

conditions)

IT **36894-69-6, Labetalol 107724-20-9, Eplerenone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aldosterone receptor antagonist and α-adrenergic modulators combination therapy for prevention or treatment of pathogenic conditions)

RN 36894-69-6 HCAPLUS
CN Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 107724-20-9 HCAPLUS
CN Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>